Non-invasive Measurements of Hepatic Glycogen Levels and Glycogen Synthesis Rates Using Chemical Exchange Saturation Transfer and Comparison to 13C NMR Spectroscopy by Miller, Corin O'Dell
Non-invasive Measurements of Hepatic Glycogen Levels and Glycogen Synthesis Rates Using 
Chemical Exchange Saturation Transfer and Comparison to 13C NMR Spectroscopy 
 
By 
Corin O’Dell Miller 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
In partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
in 
Interdisciplinary Studies: Magnetic Resonance Imaging and Spectroscopic Methodology 
August, 2015 
Nashville, Tennessee 
 
 
Approved:         Date: 
_________________________________________________           _________________ 
John C. Gore, Ph.D 
_________________________________________________           _________________ 
Alan D. Cherrington, Ph.D 
_________________________________________________           _________________ 
Bruce M. Damon, Ph.D 
_________________________________________________           _________________ 
Eduard Y. Chekmenev, Ph.D 
ACKNOWLEDGEMENTS 
 
My gratitude to my wife and children for putting up with my absences during this process.   
 
My gratitude to Jin Cao and Chunlian Zhang for their technical expertise and assistance with 
these studies. 
 
My gratitude to both by advisors John Gore and Alan Cherrington who supported me throughout 
this lengthy and sometimes tortuous process, and who were continually willing to find creative 
ways to allow me to pursue this research, and to the other members of my PhD committee, 
Bruce Damon and Eduard Chekmenev, for their invaluable help and insight. 
 
My gratitude to all my managers at Merck who supported me throughout this process, Richard 
Hargreaves, Donald Williams, Jeffrey Evelhoch, and Richard Kennan.  
 
 
 
 
 
 
ii 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS  .......................................................................................................... ii 
LIST OF TABLES  ...................................................................................................................... vi 
LIST OF FIGURES  .................................................................................................................. vii 
LIST OF ABBREVIATIONS  ........................................................................................................ x 
 
Chapter 
 
I.     Glycogen and its Physiological and Metabolic Importance  .................................................. 1 
 
       Glycogen Structure and Tissue Distribution  ......................................................................... 1 
       Glycogen Metabolism and its Controls  ................................................................................ 4 
       Pharmacological Effectors of Glycogen Metabolism  ............................................................ 9 
 
II.    Measurement Methods for Tissue Glycogen  ..................................................................... 12 
 
       Tissue Biopsy  .................................................................................................................... 12 
       13C MR Spectroscopy  ........................................................................................................ 12 
       CEST Methods for Glycogen Detection  ............................................................................. 17 
 
III.   Theoretical Description of Chemical Exchange Saturation Transfer  .................................. 21 
 
       Introduction  ....................................................................................................................... 21 
       Two Pool Model of Chemical Exchange  ............................................................................ 21 
       Weal Saturation Pulse Approximation  ............................................................................... 23 
       Steady-State Solutions Under the WSP Approximation  ..................................................... 23 
       Time-Dependent Solutions Under the WSP Approximation  ............................................... 25 
       The Magnetization Transfer Ratio  ..................................................................................... 26 
 
IV.   Phantom Studies and Optimization of CEST Parameters  ................................................. 28 
 
      Introduction  ........................................................................................................................ 28 
iii 
 
      Methods  ............................................................................................................................. 28 
           NMR Acquisitions  .......................................................................................................... 29 
           Data Analysis  ................................................................................................................ 29 
      Results and Discussion  ...................................................................................................... 31 
      Conclusion  ......................................................................................................................... 33 
 
V.   Measurements of Total Glycogen in Perfused Livers  ......................................................... 33 
 
       Introduction ........................................................................................................................ 34 
       Methods  ............................................................................................................................ 34 
       Results and Discussion  ..................................................................................................... 37 
       Conclusion  ........................................................................................................................ 43 
 
VI.  Measurements of Glycogen Synthesis Rates in Perfused Livers  ....................................... 44 
 
       Introduction  ....................................................................................................................... 44 
       Methods  ............................................................................................................................ 44 
       Results and Discussion  ..................................................................................................... 46 
       Conclusion  ........................................................................................................................ 50 
 
VII. Direct Effects of AMPK Activation on Hepatic Glycogen Synthesis Rates  .......................... 51 
 
       Introduction  ....................................................................................................................... 51 
       AMPK Biology  ................................................................................................................... 51 
       Description of Small Molecule AMPK Activator MK-8722  .................................................. 54 
       Methods  ............................................................................................................................ 56 
       Results and Discussion  ..................................................................................................... 57 
       Conclusion  ........................................................................................................................ 59 
 
VIII. CEST Imaging in vivo at 7T  .............................................................................................. 60 
 
        Introduction  ...................................................................................................................... 60 
        Methods  ........................................................................................................................... 60 
Phantom Studies  .......................................................................................................... 60 
MRI Acquisitions ............................................................................................................ 60 
iv 
 
Animal Protocol  ............................................................................................................ 61 
Data Analysis  ............................................................................................................... 62 
      Results and Discussion  ...................................................................................................... 65 
      Conclusion  ......................................................................................................................... 70 
 
IX.  Summary and Future Directions  ........................................................................................ 71 
 
Appendix 
 
A.   Matlab Data Processing Code 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
LIST OF TABLES 
 
Table 
 
1.     Power calculation for detection of changes in glycogen synthesis rates  ........................... 48 
2.     In vitro profile of MK8722 against AMPK isoforms  ............................................................ 55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
LIST OF FIGURES 
 
Figure 
 
1.        Schematic of glycogen structure  ..................................................................................... 2 
2.        Pathway of direct glycogen synthesis and controls  .......................................................... 5 
3.        Control of hepatic glucose uptake and glycogen synthesis in vivo  ................................... 8 
4.        Schematic of nuclear spins in a magnetic field  .............................................................. 13 
5.        Schematic of NMR time domain and spectral signals  .................................................... 14 
6.        Illustration of CEST phenomena and methods to quantify CEST  ................................... 19 
7.        Modelling procedure to calculate MTRasym  ..................................................................... 27 
8.        Results from glycogen phantom studies  ........................................................................ 32 
9.        Calibration curve for 13C MRS measurements of glycogen  ............................................ 33 
10.      Protocol for measurement of total glycogen in perfused livers  ....................................... 35 
11.      Monte Carlo error simulation protocol  ............................................................................ 37 
12.      Sample 13C MRS and CEST data  .................................................................................. 38 
13.      Dependence of CEST-13C MRS correlation on MTRasym integration region  .................... 39 
14.      Correlation of CEST and 13C MRS measurements of total glycogen .............................. 40 
15.      Protocol for measurement of glycogen synthesis in perfused livers  ............................... 45 
16. Illustration of data analysis protocol for 13C MRS and CEST measurement of      
glycogen synthesis rates  .............................................................................................. 46 
17. CEST and 13C MRS measurements of glycogen synthesis rates for livers under    
different starting conditions  ........................................................................................... 47 
18. CEST and 13C MRS measurements of glycogen synthesis rates for livers treated         
ex-vivo with glucagon  ................................................................................................... 48 
19.       Correlation of CEST and 13C MRS measurements of glycogen synthesis  .................... 50 
20. Effects of AMPK activation on metabolic pathways  ....................................................... 52 
21. Chemical structure of small molecule AMPK activator MK8722  .................................... 54 
22. Effects of MK8722 on pACC in vivo and on DNL in vitro  ............................................... 56 
23. Acute effect of AMPK activation on hepatic glycogen synthesis .................................... 58 
vii 
 
24. In vivo protocol for measurement of glycogen synthesis rates  ...................................... 62 
25. Illustration of procedure to correct for B0 inhomogeneity  ............................................... 63 
26. Illustration of the method to calculate the change in the MTRasym over time  .................. 64 
27. Illustration of the pixel by pixel analysis protocol  ........................................................... 65 
28. Data from glycogen phantom studies at 7T  .................................................................. 66 
29. Sample anatomical images and CEST slice  ................................................................. 67 
30. Blood glucose at the beginning and end of the glucose infusion  ................................... 67 
31. Average increase of the MTRasym over time in vivo  ....................................................... 68 
32.      Comparison of MTRasym slope versus time for the liver and spine region ....................... 69 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
LIST OF FREQUENTLY USED SYMBOLS AND ABBREVIATIONS 
 
NMR – Nuclear magnetic resonance 
MRS – Magnetic resonance spectroscopy  
CEST – Chemical exchange saturation transfer 
MTRasym – Magnetization transfer ratio asymmetry 
AUC – Area under the curve 
PTR – Proton transfer ratio 
SNR – signal to noise ratio 
WSP – Weak saturation pulse 
DWS – Direct water saturation 
AMPK – AMP-activated protein kinase 
GSase – Glycogen synthase 
GPase – Glycogen phosphorylase 
GK – Glucokinase 
ACC – Acetyl CoA carboxylase 
G6P – Glucose-6-phosphate 
DNL – de novo lipognesis 
RF – Radiofrequency 
B0 – Static magnetic field 
B1 – Applied magnetic field orthogonal to B0 
R1 – Longitudinal relaxation rate 
R2 – Transverse relaxation rate 
T1 – Longitudinal relaxation time (1/R1) 
T2 – Transverse relaxation time (1/R2) 
k – Chemical exchange rate 
ω – Frequency 
ANOVA – Analysis of variance 
EC50 – Concentration of 50% excitation
ix 
 
CHAPTER I 
GLYCOGEN AND ITS PHYSIOLOGICAL AND METABOLIC IMPORTANCE 
 
Glycogen Structure and Tissue Distribution 
Glycogen is a highly branched polymeric form of glucose that serves as the 
primary carbohydrate energy storage depot in mammalian cells.  In the post-prandial 
state, ingested carbohydrates are stored as glycogen in the liver and muscle.  During 
exercise, muscle glycogen is degraded to provide fuel for contraction.  In periods of 
fasting or hypoglycemia, liver glycogen is broken down to glucose and released into the 
blood to provide energy for other tissues.  As such, glycogen plays a key role in whole 
body glucose homeostasis and energy metabolism.   
Polymerization in glycogen is achieved via α-1,4-glycosidic linkages between 
glucose units while branch points are introduced by α-1,6-glycosidic linkages (Figure 
1A).  Glycogen molecules are of varied sizes and branch points are not in precisely 
defined locations, and thus glycogen molecules of identical mass may have different 
chemical structures.  A well-accepted model for glycogen structure (Gunja-Smith, 1970; 
Melendez-Hevia, 1993; Melendez, 1997; Goldsmith, 1982) categorizes the chains as 
inner B-chains, containing two branch points, and unbranched outer A-chains (Figure 
1B).  Analysis of mammalian glycogen suggests that the average chain length is 
approximately 13 glucose residues (Melendez-Hevia, 1993; Melendez, 1997) and that 
glycogen is made up as a series of tiers. An important structural feature is that the 
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outermost tier of any completely formed glycogen molecule contains approximately half 
of the total glucose residues of the molecule as unbranched A-chains. 
 
Figure 1. Schematic of glycogen structure.  (A) Individual bonds between glucose molecules.  
(B) Model of a single glycogen molecule.  (C) Model of a glycogen particle consisting of 
glycogen and representative associated proteins.  Acronyms not defined in the text are as 
follows: PP1c – protein phosphatase type 1 catalytic subunit; GL, RGL, PTG – PP1 glycogen 
targeting subunits; LF – laforin;Stbd1 – starch-binding domain protein 1; (Reprinted from Roach, 
2012) 
 
Glycogen is known to form complexes with other small molecules, such as 
glucosamine (Kirkman, 1986; Kirkman, 1989) and phosphate (Fontana, 1980; Lomaka, 
1984).  Glycogen also forms complexes with associated proteins as shown 
schematically in Figure 1C (Roach, 2012).  Fischer and colleagues were the first to 
partially purify ‘glycogen particles’ from muscle, which contained glycogen, proteins, and 
components of the sarcoplasmic reticulum (Meyer, 1970; Heilmeyer, 1970; Haschke, 
1970).  These particles result from the binding of certain proteins to glycogen, to each 
other, and also to membranes. Known proteins that associate with glycogen include the 
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glycogen synthesis initiator glycogenin (GN), enzymes involved in glycogen synthesis 
and degradation such as glycogen synthase (GSase), glycogen phosphorylase 
(GPase), and the glycogen debranching enzyme (DBE), and several regulatory proteins 
including phosphorylase kinase (PH kinase) and members of the protein phosphatase-
1G (PP1c) family. In addition, the β-subunit of AMP-activated protein kinase (AMPK) 
has a glycogen-binding domain (Hudson, 2003; Polekhina, 2003) and is thought to play 
a role in the regulation of glycogen synthesis (McBride, 2009; Winnick 2011). 
Glycogen is distributed throughout many tissue types in the body, but the sites in 
which highest concentrations of glycogen are observed are liver and muscle.  As 
glycogen molecules are non-uniform in structure and thus do not have a consistent 
molecular weight, concentrations of tissue glycogen are typically reported in units of 
glucose equivalents per gram or per volume of tissue.  Liver glycogen concentrations 
are normally in the 40-80 mg/g (200-400 mM) range (Wikipedia; Greutter 1994; Winnick, 
2013), although under extreme glycogen loading conditions, reports of levels near 100 
mg/g (500 mM) have been reported (Winnick, 2011).  Liver glycogen is unique in that it 
functions as a storage depot under conditions of elevated circulating glucose (e.g. after 
a meal), and also as a supply of glucose to be released to the other tissues during 
periods of fasting or hypoglycemia.  Muscle glycogen levels are lower than liver, 
typically in the 10-20 mg/g (50-100 mM) range, with a reported upper limit of 40 mg/g 
(Wikipedia; Hansen, 1999), although more glycogen is stored in muscle on a whole-
body basis since muscle tissue is much more abundant than liver.  Muscle glycogen 
also serves as a primary site of glucose disposal during post-meal conditions (Shulman 
1990), however because muscle lacks the glucose-releasing enzyme glucose-6-
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phosphatase (G6Pase), muscle glycogen can only supply local muscle cells with 
glucose.  The amounts and roles of glycogen in other tissues are generally less clear 
and not as well studied.  Approximate glycogen levels in other tissues are as follows:  
brain – 1 mg/g (Choi 2003; Oz, 2007), heart – 5 mg/g (Daw, 1968; Nakao, 1993), 
adipose – 1 mg/g (Jurczak, 2007). 
 
Glycogen Metabolism and its Controls 
In the liver, glycogen can be synthesized either from glucose, or from three-
carbon precursors.  These two pathways are termed the direct and indirect pathways, 
respectively.  The contribution of the indirect pathway to glycogen synthesis is less well 
studied and varies depending on species and diabetic state (Huang, 1988; Moore, 
1991; Hellerstein, 1993; Hwang, 1993).  The direct pathway of glycogen synthesis and 
its controls, however, are well known.  The biochemical pathways of hepatic glycogen 
metabolism, and their main controls, are shown in Figure 2.  Several enzymes and 
regulatory proteins are involved in the regulation of hepatic glycogen synthesis.  The 
bidirectional glucose transporter GLUT2 mediates transport of glucose into the liver cell.  
The first reaction of glycogen synthesis is the phosphorylation of glucose to glucose 6-
phosphate (G6P), catalyzed by glucokinase (GK), the liver-specific isoform of 
hexokinase.  G6P is then converted into glucose 1-phosphate (G1P) by 
phosphoglucomutase, and then to uridine diphosphate glucose (UDPG) by UDPG 
pyrophosphorylase.  In the final step of glycogen synthesis, GSase catalyzes the 
transfer of glucose units from UDPG to glycogen by synthesis of α-1,4 bonds, while the 
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glycogen branching enzyme (GBE) transfers a chain of six to eight glucosyl units to a 
C6 to form an α-1,6 branch.   
 
Figure 2.  Pathway of hepatic glycogen metabolism (assuming direct synthesis from glucose) 
and its controls.  Abbreviations not given in the text are as follows: GKRP – glucokinase 
regulatory protein; PKs – protein kinases; PP1 – protein phosphatase-1. (Reprinted from Agius, 
2008).    
 
Glycogen breakdown, for the most part, proceeds as the reverse of glycogen 
synthesis with the two key exceptions: (1) GSase is replaced by GPase and (2) the 
glycogen branching enzyme is replaced with the glycogen debranching enzyme (GDE).  
GPase catalyzes the degradation of glycogen by phosphorolysis of the α-1,4 bonds to 
form G1P.  This process stops, however, when there are only four remaining glucose 
units from a branch point and cannot proceed further without GDE.  GDE transfers three 
glucose units to a nearby branch and removes the final glucose unit, thereby completely 
removing the branch.  In the case where the degraded glycogen is to be released from 
the liver into the circulation as free glucose, then GK is replaced by G6Pase. 
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Glycogen synthesis and degradation are subject to many layers of regulation, 
provided by small molecules, enzymes, and regulatory proteins.  GK is acutely 
regulated by association/dissociation from a binding protein called glucokinase 
regulatory protein (GKRP), which acts as a nuclear-binding protein for GK (van 
Schaftingen, 1992; Choi, 2013).  Cytoplasmic GK is stabilized via interactions with the 
bifunctional enzyme PFK2/FBPase which preserves GK’s function as a ‘glucose sensor’ 
and also promotes a coordination of glucose phosphorylation and glycolysis (Massa, 
2004).  GK gene expression is upregulated by insulin while glucagon suppresses GK 
expression (Iynedijan, 1993).  GSase is regulated by multi-site phosphorylation events, 
all of which cause varying degrees of inactivation (Roach, 2011). Conversely, activation 
of GSase via dephosphorylation is catalyzed by glycogen synthase phosphatase (GSP).  
G6P, the first intermediate in glucose metabolism, activates GSase in the following two 
ways: (1) by allosteric stimulation of the phosphorylated (inactive) form and (2) by 
inducing conformational changes that make it a better substrate for dephosphorylation 
(Villar-Palasi, 1997).  It is generally accepted that the allosteric stimulation of GSase by 
G6P is stronger than any effects on phosphorylation or dephosphorylation.  GPase is 
regulated by phosphorylation of a single residue at the N-terminus, catalyzed by PH 
kinase.  The phosphorylated, activated form of GPase, (GPa) catalyzes the degradation 
of glycogen and is also an allosteric inhibitor of GSP.  The phosphorylation state of 
GPase thus regulates both glycogen synthesis and degradation. The conversion of GPa 
into the dephosphorylated, inactive form of GPase (GPb) is catalyzed by protein 
phosphatase-1 and has been shown to be regulated by both glucose and G6P, which 
make GPa a better substrate for dephosphorylation  (Agius, 2008). 
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In an integrated whole body physiology sense, hepatic glycogen metabolism is 
regulated in vivo by three primary factors shown in Figure 3 (Moore, 2012), the portal 
vein glucose concentration, the difference between the portal vein and hepatic artery 
glucose levels, known as the ‘portal signal’ (Myers, 1991; Pagliassotti, 1996), and the 
prevailing hormonal concentrations.  Insulin serves to augment hepatic glycogen 
synthesis (although mostly in the presence of a portal signal and an increased glucose 
load) (Cherrington, 1999) and to suppress glycogen breakdown via signaling through 
insulin receptor substrates (IRS) and the protein kinase B (aka AKT) pathway which 
results in inactivation of glycogen synthase kinase (GSK), leading to de-phosphorylation 
and activation of GSase (Saltiel, 2001).  Glucagon increases hepatic glucose production 
through inhibition of glycogen synthesis and induction of glycogen breakdown by 
signaling through cyclic AMP and protein kinase A, which results in activation of PH 
kinase and subsequent activation of GPase (Jiang, 2003; Ramnanan 2011).  Other 
hormones have an effect on glycogen metabolism as well.  Epinephrine was shown to 
transiently increase glycogen breakdown while also increasing gluconeogenesis (Chu, 
1997), and norepinephrine was shown to increase glycogen breakdown alone (Chu, 
1998). 
Although the biochemical pathways of glycogen metabolism are the same in liver 
and muscle, three primary differences exist in the control of muscle glycogen 
metabolism.  First, the muscle glucose transporter (GLUT4) is not embedded in the cell 
membrane like GLUT2, rather it translocates to the cell membrane in response to 
insulin.  So while the primary determinant of hepatic glucose uptake is the glucose load, 
the primary determinant of muscle glucose uptake is the ambient insulin level.  Second, 
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muscle hexokinase has a much lower Km for glucose than GK (~0.1mM vs 10mM, 
respectively), and thus intracellular glucose is more rapidly phosphorylated in muscle 
resulting in potentially much higher levels of G6P in muscle than liver.  Lastly, muscle 
does not express G6Pase and therefore cannot release glucose into the circulation like 
liver. 
 
Figure 3.  The physiological controls of hepatic glucose uptake and glycogen metabolism in 
vivo.  (Reprinted from Moore, 2012).  
 
While it is well established that glycogen levels represent the net result of the 
integration of many complex metabolic control processes, recent evidence has shown 
that glycogen levels themselves may be capable of exerting metabolic effects.  For 
example, the well-known glucose secretory response of the liver to periods of 
hypoglycemia has recently been shown to be augmented in livers with increased 
glycogen content (Winnick, 2012).  Additionally, in both liver (Winnick, 2013 ) and 
8 
 
muscle (Jensen, 2006), elevated glycogen levels have been shown to suppress further 
glycogen synthesis and it has been shown that this effect may be mediated at least in 
part via interaction of glycogen with the glycogen binding domain on AMPK (Hardie, 
2008). 
 
Pharmacological Effectors of Glycogen Metabolism 
As glycogen is intimately linked to whole body glucose homeostasis, several of 
the key control points of glycogen metabolism have emerged as pharmacological 
targets for the treatment of diabetes.   
GK activators have received much attention, although much of this is due to the 
additional role of GK in the pancreatic β cell’s glucose-stimulated insulin secretion 
response (Henquin, 2000; Newgard, 2001).  Nonetheless, liver-targeted GK activators 
may also provide a useful therapeutic effect.  Hepatic GK expression is insulin 
dependent, and human and animal models of type 2 diabetes generally have reduced 
GK (Caro, 1995; Torres, 2009).  Furthermore, inactivating mutations in GK result in 
diabetic phenotypes, particularly the so-called mature-onset diabetes of the young 
(MODY).  Small molecule GK activators have been developed and have been shown to 
lower circulating glucose, stimulate insulin release, and reduce hepatic glucose 
production in humans and in preclinical models of diabetes (Matschinsky, 2011).  Issues 
with this class of therapies largely have revolved around the risk of hypoglycemia due to 
the activation of pancreatic GK and the resultant large increase in insulin release.  This 
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suggests that a liver-targeted GK activator may have a more optimal efficacy/safety 
profile.  
As GPase is the rate controlling step in the breakdown of glycogen and 
subsequent release from the liver, it too represents a potential pharmacological target.  
Several different small molecule inhibitors, binding to different sites on the enzyme, 
have ameliorated hyperglycemia and other symptoms related to diabetes in animal 
models of type II diabetes (Baker, 2006).  Key issues in the development of this class of 
therapies include isoform specificity (GPase is also expressed in the muscle and brain) 
and also a greater understanding of the effects of removing a part or all of such a vital 
fuel source, especially during periods of exercise and fasting. 
Upon the discovery that muscle glycogen synthesis was markedly reduced in 
type II diabetic humans under hyperglycemic-hyperinsulinemic conditions (similar to 
those observed after a meal) (Shulman 1990), muscle GSase became a novel target for 
type II diabetes.  In particular, inhibitors of glycogen synthase kinase 3 (GSK3) were 
developed as a means of activating GSase.  Several small molecule inhibitors of GSK3 
showed insulin-like effects in preclinical diabetic models including increased GLUT4 (the 
muscle glucose transporter) translocation to the plasma membrane, activation of 
glucose uptake and glycogen synthesis in muscle cells, and suppression of 
gluconeogenic enzymes (Eldar-Finkelman, 2003).  These effects generally led to 
improvements in oral glucose tolerance.  The key issue in the development of GSK3 
inhibitors is the enzyme’s role in the regulation of cell mitosis and the potential for risks 
of carcinogenicity. 
10 
 
In other cases, pharmacological targets may have unexpected impacts on 
glycogen metabolism.  For example, activation of AMPK was shown to directly 
phosphorylate and inhibit GSase in vitro (Carling, 1989), yet a recent study 
demonstrated that mice treated with an AMPK activator paradoxically had increased 
muscle glycogen levels (Hunter, 2011).  Further analysis revealed that the effect of 
AMPK activation to directly increase muscle glucose uptake via increased GLUT4 
translocation and subsequently increase intracellular levels of G6P, was able to override 
the direct inhibitory effects of AMPK on GSase alone.  This finding was consistent with 
the idea that G6P is the strongest modulator of GSase activity and reinforces the idea 
that glycogen synthesis in vivo represents the sum of potentially many different 
processes, and cannot always be predicted from individual in vitro data alone.  
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CHAPTER II 
MEASUREMENT METHODS FOR LIVER GLYCOGEN 
 
Tissue Biopsy 
As glycogen is confined to intracellular locations, robust and reliable 
measurements of liver glycogen content have been problematic.  Biochemical assay of 
glycogen following a tissue biopsy is the oldest measurement method.  This approach 
generally consists of homogenization and extraction of glycogen from a frozen tissue 
sample, followed by either enzymatic or chemical degradation of glycogen to glucose 
and subsequent assay of glucose concentrations via clinical chemistry analyzers or 
traditional glucose assay kits.  The tissue biopsy method is limited by its invasive 
nature, along with the potential for regional variation within the liver (Moore, 1991) and 
these shortcomings have generally limited the clinical utility of this approach. 
 
13C Magnetic Resonance Spectroscopy 
The ability to measure glycogen non-invasively in liver with 13C magnetic 
resonance spectroscopy (MRS) was demonstrated approximately 25 years ago (Jue, 
1987; Avison, 1988).  The basic principles of MRS have been described in a number of 
reviews (Roden, 1999; Shulman 2001) and are discussed only briefly here.  Certain 
nuclei possess a magnetic moment or “spin” which in the absence of any external 
magnetic influence will be randomly oriented.  When placed inside a strong, static 
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magnetic field generated by a nuclear magnetic resonance (NMR) spectrometer or 
magnetic resonance imaging (MRI) scanner, the nuclei will precess around the direction 
of the external magnetic field (generally assigned as the +Z direction) with a 
characteristic frequency called the Larmor frequency.  These nuclear spins can align 
either parallel or antiparallel to the magnetic field and at equilibrium, more will align 
parallel to the field due to the lower energy state, generating a net magnetization in the 
+Z direction.  This is shown schematically in Figure 4. 
 
Figure 4. Schematic of nuclear spins in random orientations (left) and aligned parallel or 
antiparallel with an external magnetic field (right).  (Image taken from ‘Basics of NMR’ online 
course, https://www.cis.rit.edu/htbooks/nmr/) 
 
Excitation of these nuclei by an additional orthogonal oscillating magnetic field at 
the Larmor frequency (generally in the radiofrequency range) temporarily tips the spins 
of these nuclei out of alignment with the external field into the x-y plane.  In the process 
of returning back to the low energy-state of alignment within the static magnetic field, 
energy in the form of radiofrequency (RF) waves is emitted and detected by a receiver 
coil oriented in the x-y plane.  This signal generally has a decaying oscillating pattern 
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and is termed a free induction decay (FID).  In most experimental settings, RF 
emissions from different nuclei in different chemical environments (either due to being in 
different molecules or in different tissue types) are superimposed, and the Fourier 
transformation is used to convert the time domain FID data recorded by the receiver into 
a spectrum (i.e. a display of signal intensities versus frequency) as shown in Figure 5.  
The frequency axis for an NMR spectrum is called the ‘chemical shift’ and is the 
difference (shift) in the frequency of the nuclei of interest and the base frequency of the 
spectrometer.  This scale can be in units of Hz, or more commonly, parts per million 
(ppm) with respect to the spectrometer base frequency. 
 
Figure 5.  Sample 13C MRS time domain free induction decay signal and Fourier transformed 
spectrum. (Images taken from Google Images) 
 
For 13C MRS, each resonant frequency is unique to a specific type of nuclei, 
thereby enabling one to distinguish compounds with characteristic peak frequencies in 
an NMR spectrum. The area under a particular peak is proportional to the molar amount 
of that chemical species and can be converted to standard concentration units by 
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comparison with spectra obtained from a standard solution (aka phantom) containing a 
known amount of that compound and acquired under identical conditions.   
Despite the low natural abundance (1.1%) and inherently low NMR sensitivity of 
13C (with a gyromagnetic ratio ~1/4 that of 1H), liver glycogen is present in sufficient 
quantities that it can still be detected at natural abundance with13C MRS.  13C MRS can 
also be used in combination with infusions of 13C glucose labeled at various positions to 
trace 13C incorporation into glycogen and thereby measure glycogen synthesis rates.  
This incorporation of 13C label into glycogen can increase the sensitivity of the 13C MRS 
glycogen signal by 10-20 fold depending on the experimental protocol.   
The initial reports of glycogen detection using natural abundance 13C MRS (Jue, 
1987; Avison, 1988) were soon followed by the demonstration that in vivo glycogen was 
100% visible by MRS (Gruetter, 1991), and that MRS measurements of tissue glycogen 
yielded accurate estimates of glycogen levels when compared with tissue biopsies 
(Gruetter, 1994).  Initial applications of 13C MRS to glycogen metabolism included the 
measurement of glycogen synthesis rates in liver (Jue, 1989) and muscle (Jue, 1989) 
using both natural abundance 13C MRS and [1-13C] glucose infusions.  Natural 
abundance 13C MRS was also used to measure hepatic glycogen breakdown rates 
during a prolonged fast (Rothman, 1991).  This protocol was then used as part of a 
novel method to estimate rates of gluconeogenesis by subtracting the 13C MRS 
measured rate of glycogen breakdown from a separate isotope infusion based measure 
of whole body glucose production.  These initial reports opened the door for many 
subsequent studies examining glycogen metabolism under various conditions and also 
exploring the role of glycogen metabolism in whole body glucose homeostasis.   
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Building on these initial studies, 13C MRS measurements of glycogen were then 
applied to understanding defects of glycogen metabolism in type I and II diabetes 
mellitus.  In one of the early landmark clinical studies, it was shown that under 
hyperglycemic-hyperinsulinemic conditions (similar to those observed after a meal), 
type II diabetic subjects exhibited a reduction in muscle glycogen synthesis (Shulman, 
1990).  When these rates were extrapolated to the whole body, it was concluded that 
muscle glycogen synthesis accounted for the majority of whole body glucose uptake 
and non-oxidative glucose metabolism and that this defect was likely to be a primary 
cause of the observed post-meal hyperglycemia in the type II diabetic subjects.  Follow 
up studies used 13C MRS to help dissect the potential causes of this impairment in 
muscle glycogen synthesis (Rothman, 1995; Cline, 1997).  Previously, it was thought 
that flux through GSase was the key rate controlling step in glycogen synthesis, 
however data from these studies pointed to defects in muscle glucose transport and/or 
phosphorylation as being primarily responsible for the observed resistance to insulin-
stimulated glycogen synthesis in muscle.   
 Investigations of hepatic glucose metabolism using 13C MRS also yielded 
valuable insights into the diabetic state.  Indirect measurements of gluconeogenesis as 
described previously above revealed that type II diabetic subjects exhibited increased 
rates of gluconeogenesis after an overnight fast (Magnusson, 1992).  Additionally, type I 
diabetic subjects exhibited reduced hepatic glycogen synthesis after a mixed meal 
challenge (Hwang, 1995).  These initial demonstrations of defects in tissue glycogen 
metabolism in diabetic subjects were followed by much more detailed work in liver and 
muscle which incorporated molecular biology measurements along with 13C MRS in an 
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attempt to elucidate the mechanisms of insulin resistance in these tissues.  Detailed 
reviews of these findings have been given elsewhere (Savage, 2007; Samuel, 2010) 
and are not appropriate here, however it should be stated that the results of these 
studies provided the basis for current theories of lipid induced insulin resistance and its 
role in diabetes.      
Despite these advances, in vivo 13C NMR spectroscopy still remains 
handicapped by its inherently low signal to noise ratio (SNR) due to the low natural 
abundance and the low gyromagnetic ratio of the 13C nucleus, as well as the cost of the 
often required 13C labeled isotopes. Furthermore, the vast majority of clinical MRI 
scanners lack 13C detection capability, and clinical adaptation of this technology will 
likely remain within the research community only.  
 
CEST Method for Glycogen Detection 
Recently, a novel MRI method for detection of tissue glycogen was reported (van 
Zijl, 2007) based on sensing the chemical exchange of glycogen hydroxyl protons with 
tissue water.  This method is generally referred to as chemical exchange saturation 
transfer (CEST).  In general, this method is relatively straightforward to implement on 
current NMR spectrometers and MRI imaging systems, because only proton detection is 
required (e.g. Zhou, 2011; Longo, 2014).  However, whether it can reliably measure 
physiological concentrations of glycogen, and what other factors affect its accuracy, 
have not been established.  The basis of CEST detection of glycogen via exchange of 
hydroxyl protons is shown schematically in Figure 6 where the 1H NMR signal from a 
17 
 
relatively small solute pool with exchangeable protons, glycogen in this case (Figure 
6A), can be indirectly detected via saturation with NMR pulses, transfer of these 
saturated protons to the hydroxyl functional groups to water, and subsequent 
measurement of the attenuation of the water 1H NMR signal (Figure 6B).  This 
saturation transfer process is repeated for multiple frequency offsets from water and the 
resulting series of water peaks acquired at these frequency offsets (ω) is typically called 
a ‘Z-spectrum’ (Figure 6C), and is used to calculate the Magnetization Transfer Ratio 
Asymmetry (MTRasym) (Figure 6D) as:  
MTRasym(ω) = [S(-ω ) – S(ω )]/S0     (1) 
Here, S represents the water signal observed at a saturation offset ω from the water 
resonance, and S0 is the water signal observed at a saturation offset far (>20 ppm) from 
the water resonance where no CEST saturation effects are expected to be present.  
Note that Ihave adopted the standard convention in CEST studies of defining the water 
resonance to be 0 ppm.  Most reported measures of CEST are based on this MTRasym 
parameter, though for some choices of the saturation parameters there may be factors 
other than chemical exchange that influence measured values of MTRasym.   
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 Figure 6. Illustration of the CEST phenomena (A) and (B), and traditional methods used to 
quantify CEST (C) and (D) (Adapted with permission from van Zijl, 2007).  
 
Proton CEST approaches benefit from increased SNR compared to 13C MRS and 
also from the wide availability of 1H MR hardware.  The use of CEST based approaches 
to detect other –OH and –NH containing metabolites has been recently reported for 
glycosaminoglycans (Ling, 2008), creatine (Kogan, 2014), glutamate (Cai, 2012), 
glucose (Chan, 2012), and 2-deoxy-glucose (Nasrallah, 23; Rivlin, 2013).  Despite the 
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demonstration of proof of concept for detection of these metabolites, the optimization, 
calibration, and quantification in the tissue of interest using CEST has, for the most part, 
not yet been reported.  Furthermore, in the initial report of CEST-based detection of 
glycogen (van Zijl, 2007), there appeared to be a non-linear and saturating relationship 
between the amount of glycogen and the CEST signal measured in phantoms over the 
expected physiological range, calling into question the utility of this approach for 
measurements of physiological levels of liver glycogen.   
The overall the goals of this work were therefore as follows:  (1) to develop 
optimal acquisition parameters for both 13C MRS and CEST measurements of glycogen 
at 11.7T using phantoms with glycogen amounts over the expected physiological range, 
(2) to develop protocols using 13C MRS and CEST methods to measure total liver 
glycogen in perfused livers at 11.7T, and (3) to develop physiological protocols to 
combine with the 13C MRS and CEST methods to measure glycogen synthesis rates 
both in perfused livers at 11.7 T, and in vivo at 7T using CEST alone.  Additionally, as 
an application of this methodology, I sought to utilize these methods to address a novel 
pharmacological question, specifically, the effects of acute activation of AMPK on 
hepatic glycogen synthesis in perfused livers.   
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CHAPTER III 
CHEMICAL EXCHANGE SATURATION TRANSFER THEORY 
 
Introduction 
Here I will describe the theoretical aspects of CEST for a two pool system with 
glycogen being the solute of interest and water being the solvent.  The analysis is 
similar to that described in Zhou, 2006.  For such a system, chemical exchange 
processes are commonly described by the Bloch equations with exchange terms 
included.  These are sometimes called the Bloch–McConnell equations (McConnell, 
1958).  In general, it is difficult to obtain analytical solutions of these equations, and so I 
will use some reasonable assumptions, where convenient, to gain insight into the 
factors affecting the CEST signal.   
 
Two Pool Model of Chemical Exchange 
Figure 6A shows a schematic for the two exchanging pools, a small pool of 
glycogen with exchangeable –OH protons (g) and a large pool of bulk water protons (w).  
These two pools have relaxation rates and initial magnetizations of R1g, R2g, and M0g, 
and R1w, R2w, and M0w, respectively.  The analysis starts with the usual Bloch equations 
in the rotating reference frame for each of the two pools shown in Figure 6A.  To 
account for the effects of relaxation, the terms -R2Mx, -R2My, -R1(M0-Mz) are added to 
the x, y, and z components, respectively, of glycogen and water in the Bloch equations.  
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To account for the effects of chemical exchange, the terms ± kMx, ± kMy, and ± kMz are 
also respectively added to the x, y, and z components of glycogen and water, with the 
sign being determined by the direction of the exchange.  For the current two pool model, 
we make the following definitions: ω0=γB0, ω1=γB1 (where γ is the nuclear gyromagnetic 
ratio, B0 is the main magnetic field, and B1 is the applied radiofrequency field).  Working 
in the rotating frame, WE define Δωg=ωg−ω0 and Δωw=ωw−ω0 which results in the 
components of the vector 𝜔𝜔�⃑  being (-ω1, 0, Δωg) and (-ω1, 0, Δωw) for glycogen and 
water, respectively.  When written for each pool, including both relaxation and chemical 
exchange terms, the Bloch equations become:   
dMxg/dt =−ΔωgMyg−R2gMxg−kgwMxg+kwgMxw    (2) 
dMyg/dt =ΔωgMxg+ω1Mzg−R2gMyg−kgwMyg+kwgMyw   (3) 
dMzg/dt =−ω1Myg−R1g(Mzg−M0g)−kgwMzg+kwgMzw    (4) 
dMxw/dt =−ΔωwMyw−R2wMxw+kgwMxg−kwgMxw    (5) 
dMyw/dt = ΔωwMxw+ω1Mzw−R2wMyw+kgwMyg−kwgMyw   (6) 
dMzwdt =−ω1Myw−R1w(Mzw−M0w)+kgwMzg−kwgMzw   (7) 
The number of differential equations can be reduced and some terms omitted under 
certain assumptions, the most common of which is the weak saturation pulse (WSP) 
approximation (Forsen, 1963; Zhou, 2004), in which no direct water saturation occurs.  
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Weak Saturation Pulse Approximation 
The simplest approximation is to assume that the RF field is applied only to the 
pool of glycogen protons (g) with the pool of water protons (w) left unperturbed.  Under 
these conditions, we have Δωg=0 and Δωw→∞. Further assuming complete saturation 
(cs) of the irradiated protons, a simple solution can be obtained from Eq. (7): 
Mzwcs  = M0w[R1w/(R1w+kws)]       (8)  
The proton transfer ratio (PTR), in general, can be defined as: 
PTR = (M0w – Mzw)/M0w       (9)  
Therefore, when pool s is completely saturated, the proton transfer ratio (PTR) for the 
water signal can be derived to be: 
PTRcs = kws/(R1w+kws)       (10) 
While this is an interesting result from the simplest case, complete saturation can be 
obtained only under a very strong RF field, which is not a true case.  
 
Steady-State Solutions Under the WSP Approximation 
We now use the case-sensitive definitions: mzg=Mzg−M0g, mzw=Mzw−M0w, r1g=R1g+kgw, 
r1w=R1w+kwg, r2g=R2g+kgw, and r2w=R2w+kwg. If the RF field is applied to glycogen protons 
only, equations (2) – (7) can be simplified to: 
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dMyg/dt = ω1mzg − r2gMys + kwgMyw + ω1M0g    (11) 
dmzg/dt = −ω1Myg − r1gmzg + kwgmzw     (12) 
dMyw/dt = −r2wMyw + kgwMyg       (13) 
dmzw/dt = −r1wmzw + kgwmzg       (14) 
The steady-state (ss) solutions of these four equations can be obtained by setting the 
left hand sides of equations (11) – (14) equal to zero, and the results can be expressed 
as 
 𝑚𝑚𝑧𝑧𝑧𝑧
𝑠𝑠𝑠𝑠 =  − 𝜔𝜔12𝑀𝑀0𝑔𝑔
𝜔𝜔1
2 +𝑝𝑝𝑝𝑝        (15) 
𝑀𝑀𝑦𝑦𝑧𝑧
𝑠𝑠𝑠𝑠 =  −𝜔𝜔1𝑝𝑝𝑀𝑀0𝑔𝑔
𝜔𝜔1
2 +𝑝𝑝𝑝𝑝          (16) 
𝑚𝑚𝑧𝑧𝑧𝑧
𝑠𝑠𝑠𝑠 =  −𝑘𝑘𝑔𝑔𝑔𝑔
𝑟𝑟1𝑔𝑔
𝜔𝜔1
2𝑀𝑀0𝑔𝑔(𝜔𝜔12 +𝑝𝑝𝑝𝑝)        (17) 
𝑀𝑀𝑦𝑦𝑧𝑧
𝑠𝑠𝑠𝑠 =  −𝑘𝑘𝑔𝑔𝑔𝑔
𝑟𝑟2𝑔𝑔
𝜔𝜔1𝑝𝑝𝑀𝑀0𝑔𝑔
𝜔𝜔1
2 +𝑝𝑝𝑝𝑝         (18) 
where p = r2g − (kgwkwg/r2w) and q = r1g − (kgwkwg/r1w).  From here, it is convenient to 
define the labeling fraction or saturation efficiency for pool g as 
𝛼𝛼 =  − 𝑚𝑚𝑧𝑧𝑧𝑧𝑠𝑠𝑠𝑠 /𝑀𝑀0𝑧𝑧  =  𝜔𝜔12/(𝜔𝜔12 + 𝑝𝑝𝑝𝑝)      (19) 
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Time-Dependent Solutions Under the WSP Approximation 
The next assumption is to separate the process of saturation transfer into two 
consecutive steps, the first being the saturation of glycogen protons, and the second 
being the transfer of these saturated protons to water.  If the glycogen pool is 
completely isolated, its saturation rate can be estimated to be (R1s+R2s)/2, meaning that 
pool g has a saturation time constant of tens of ms (in the order of T2s). Thus, this two-
step approximation is very close to the actual situation. 
Assuming that pool s (exchangeable solute protons) approaches a steady state (𝑚𝑚𝑧𝑧𝑧𝑧𝑠𝑠𝑠𝑠 =  𝑀𝑀𝑧𝑧𝑧𝑧𝑠𝑠𝑠𝑠 −  𝑀𝑀0𝑧𝑧) instantly, the dynamics for pool w can be described by: 
dmzw/dt = −r1wmzw+kgw𝑚𝑚𝑧𝑧𝑧𝑧
𝑠𝑠𝑠𝑠
       (20) 
If Mzw(t0) = M0w (the weak pulse approximation), then mzw(t0) = 0. We have the solution 
𝑚𝑚𝑧𝑧𝑧𝑧(𝑡𝑡) =  𝑘𝑘𝑔𝑔𝑔𝑔𝑚𝑚𝑧𝑧𝑔𝑔𝑠𝑠𝑠𝑠𝑟𝑟1𝑔𝑔 �1 −  𝑒𝑒−𝑟𝑟1𝑔𝑔(𝑡𝑡−𝑡𝑡0)�      (21) 
which demonstrates that the water protons approach a steady state with a rate r1w 
(recall, r1w=R1w+kwg), which can be thought of as the spin–lattice relaxation rate of the 
water protons in the presence of RF irradiation on the glycogen protons.  Therefore, the 
PTR in the water signal can be derived to be 
𝑃𝑃𝑃𝑃𝑃𝑃 =  𝑀𝑀0𝑔𝑔− 𝑀𝑀𝑧𝑧𝑔𝑔 (𝑡𝑡𝑠𝑠𝑠𝑠𝑠𝑠)
𝑀𝑀0𝑔𝑔
        (22) 
𝑃𝑃𝑃𝑃𝑃𝑃 =  𝑘𝑘𝑔𝑔𝑔𝑔𝛼𝛼𝑀𝑀0𝑔𝑔(𝑅𝑅1𝑔𝑔+ 𝑘𝑘𝑔𝑔𝑔𝑔 )𝑀𝑀0𝑔𝑔 �1 −  𝑒𝑒−(𝑅𝑅1𝑔𝑔+ 𝑘𝑘𝑔𝑔𝑔𝑔)(𝑡𝑡𝑠𝑠𝑠𝑠𝑠𝑠)�    (23) 
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where tsat is the applied RF saturation time.  This result suggests that the PTR depends 
on the exchangeable proton concentration of glycogen (M0g ∝ [glycogen]), the chemical 
exchange rate of the glycogen protons, as well as on saturation efficiency for glycogen 
and T1 of the water.  It should be noted that at fast exchange rates, high exchangeable 
proton concentrations, and a high magnetic fields (which have lower R1w values), kwg 
may become comparable with R1w, and back exchange (water protons to glycogen 
protons) may be of influence. 
 
The Magnetization Transfer Asymmetry Ratio 
A typical CEST acquisition consists of a series of saturation pulses at varied 
frequency offsets from zero.  The resulting plot of water NMR signal versus saturation 
frequency offset is called a ‘Z-spectrum’ (Figure 6C) and is used to calculate the 
MTRasym parameter as given in equation (1).  This analysis, however, is based on the 
assumption that direct water saturation (DWS) and general magnetization transfer (MT) 
effects are symmetric about the water resonance frequency.  Recently, an alternative 
method to calculate the CEST MTRasym was proposed (Zaiss 2011), based on the 
theoretical result that under the WSP approximation the DWS portion is Lorentzian in 
shape.  Thus, when applicable, some of the studies reported here use this approach of 
fitting the experimental Z-spectrum over the non-glycogen signal containing regions to a 
Lorentzian model and then calculating the MTR asym as the difference between the 
modeled DWS and the experimental Z-spectrum.  This approach is shown 
schematically in Figure 7 below and can be very useful in cases where the Z-spectrum 
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is not centered exactly on 0 ppm as this can be incorporated into the model and used to 
correct the Z-spectrum.  
 
Figure 7. Illustration of the modelling procedure using an inverted Lorentzian fit of the DWS 
portion of the Z-spectrum to calculate the glycogen MTRasym. 
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CHAPTER IV 
PHANTOM STUDIES AND OPTIMIZATION OF CEST PARAMETERS 
 
Introduction 
In this Chapter I describe phantom studies aimed to derive optimal CEST 
acquisition parameters which yield a linear relationship with maximal measurement 
window between CEST glycogen signal and total phantom glycogen content over the 
expected physiological range. 
 
Methods 
Glycogen (oyster, Sigma-Aldrich P/N # G8751) was dissolved in a Krebs-
Henseleit buffer supplemented with 0.25% bovine serum albumin, 0.1 mM palmitate, 0.5 
mM glutamate, 0.5 mM glutamine, and 1 mM ATP (final pH = 7.4).  As the maximum 
expected concentration of liver glycogen is approximately 400 μmoles/g, and the 
maximum expected mouse liver size for the perfused liver studies was 2 g, phantoms 
were constructed with up to 800 μmoles of glycogen (measured as glucose equivalents) 
in the sensitive volume of the NMR probe.  CEST Z-spectra were acquired with varying 
saturation pulse powers and times in order to investigate which combination of 
parameters yielded a linear relationship between total phantom glycogen and the 
numerically integrated CEST MTRasym area under the curve (AUC), with maximal 
dynamic range.  It should be noted that these phantom studies were performed only to 
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determine the optimal saturation pulse parameters and were not used to calibrate the 
glycogen CEST signal.  This is because tissue glycogen will likely have different 
structural (chain length, branching, protein binding) and relaxation characteristics 
compared to glycogen in solution. 
NMR Acquisitions – All studies were performed on a Bruker 500 MHz (11.7 T) 
vertical bore NMR spectrometer using XWin-NMR 3.2 and a 20 mm TXO probe with 
13C/31P on the inner coil and 1H/2H on the outer coil with a custom fabricated 20 mm 
NMR tube.  Magnetic field lock was provided by a small (~0.5 mL) separate sealed tube 
of D2O placed inside the 20 mm NMR tube.  Natural abundance 13C NMR acquisitions 
were performed using a 15° square pulse, 1H broadband decoupling, an inter-pulse 
delay of  560 msec, and 1600 averages (22 min acquisition time).  CEST NMR 
acquisitions were performed using 32 non-uniformly spaced frequency offsets as 
follows: [±9, ±8.5, ±8, ±6, ±4, ±2.5, ±2, ±1.75, ±1.5, ±1.25, ±1, ±0.75, ±0.5, 0, 40 ppm].   
Data Analysis – 13C NMR spectra of glycogen were analyzed with peak fitting 
programs written in Matlab.  Briefly, the glycogen NMR resonances were each fit to a 
Lorentzian lineshape model, the parameters of which were optimized using a least-
squares minimization routine.  Each modeled resonance was then integrated 
analytically and the sum of the areas was calculated and used to calibrate future 
glycogen measurements in perfused livers. 
For the CEST acquisitions, all data analysis was performed using Matlab 
functions.  Z-Spectra were calculated by first numerically integrating each  magnitude 
1H NMR spectrum  between +2 and -2 ppm from the water resonance (to avoid the lipid 
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1H NMR signal) from  each saturation frequency offset.  These integrals were then 
normalized to the corresponding integral of the 1H NMR signal acquired with a 40 ppm 
frequency offset to form the Z-spectrum.  For this particular application, the Z-spectrum 
can be considered the sum of the CEST contribution and the direct water saturation 
(DWS) contribution.  As described in Chapter III, it can be shown that the DWS 
component of the Z-spectrum is theoretically inverted Lorentzian in shape. Accordingly, 
experimental Z-spectra were fit over the non-glycogen signal containing regions 
(Figure 7) with an inverted Lorentzian model given by 
𝐷𝐷𝐷𝐷𝐷𝐷(𝜔𝜔) =  𝐿𝐿0 − ℎ
4�
𝜔𝜔−𝜔𝜔0
𝐿𝐿𝐿𝐿
�
2
+1
       (24) 
where L0 is a small DC offset parameter, h is the height, ω0 is the center frequency, and 
LW is the full width at 50% peak height.  This fit was performed over the non-glycogen 
signal containing regions of the Z-spectrum using the following subset of saturation 
frequency offsets: [±9, ±8.5, ±8, ±0.1, 0, -0.25, -0.5, -0.75, -1, -1.25, -1.5, -1.75, 2 ppm 
from water] (23).  The glycogen MTRasym function was then calculated as the difference 
between the modeled DWS spectrum and the experimental Z-spectrum, i.e. 
Glycogen MTRasym(ω)  = DWS(ω) - S(ω)    (24) 
and this glycogen MTRasym curve was numerically integrated to yield the final measure 
of glycogen CEST signal.  While this Lorentzian fitting procedure may be subject to 
small errors due to the potential inclusion of NOE effects in the region used to fit the 
DWS portion of the Z-spectrum, it should be noted that the direct calculation of the 
MTRasym (eq. 1) would suffer from the same shortcoming.  Furthermore, I observed that 
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this procedure proved superior to the direct calculation of the MTRasym in our perfused 
liver studies as it allowed for any slight deviations of the 0 ppm offset to be incorporated 
into the model and corrected for. 
 
Results and Discussion 
Figure 8A shows sample Z-spectra (B1 = 4 μT, 0.5 sec) and MTRasym curves for 
total phantom glycogen amounts of 0, 200, 400, and 800 μmoles of glucose equivalents.  
Figure 8B shows a plot of total phantom glycogen versus CEST MTRasym total AUC for a 
B1 = 4 μT saturation pulse with saturation times of 0.25, 0.5, 1, and 2 seconds.  The 0.5 
sec pulse was defined as optimal based on the observation that it yielded the maximum 
dynamic range while maintaining a high degree of linearity (R2 = 0.96).  Studies with 
lower B1 values and/or longer saturation times were also performed but, as expected 
from other reports, resulted in either a reduced dynamic range or a nonlinear 
relationship.  As stated previously, these phantom studies were performed only to 
determine the optimal saturation pulse parameters for glycogen and were not used to 
calibrate the glycogen CEST signal due to expected differences in structural and 
relaxation characteristics compared to glycogen in tissue. Our RF pulse parameters and 
MTRasym values were similar to those reported in many other biomolecule CEST studies.  
I also separately studied the CEST MR signal from glucose in similarly prepared 
phantoms (data not shown) and found that the CEST signal was approximately 2-fold 
greater, consistent with the fact that free glucose has 5 exchangeable hydroxyl groups, 
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while the glucosyl units in glycogen have 2-3 exchangeable hydroxyl groups depending 
on branching within the glycogen molecule. 
 
Figure 8. Z-spectra and MTRasym curves for phantom glycogen solutions (A), and the 
relationship between total phantom glycogen and MTRasym AUC for different saturation pulse 
lengths with B1 = 4 μT (n=2). 
 
The data for 13C MRS measurements of phantom glycogen is shown below in 
Figure 9.  This data confirms that 13C MRS can accurately measure glycogen over the 
expected physiological range and will be used to calibrate 13C MRS measurements of 
glycogen in perfused livers in Chapter V.  
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 Figure 9. Calibration curve for total phantom glycogen and 13C MRS signal. 
 
Conclusion 
 These phantom studies demonstrate that it is possible to obtain acquisition 
parameters which result in a linear relationship between total phantom glycogen over 
the expected physiological range and the MTRasym AUC derived from CEST Z-spectra.  
This suggests that these parameters will be suitable for the measurement of total 
glycogen content in perfused livers as described in the next chapter. 
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CHAPTER 5 
MEASUREMENT OF TOTAL GLYCOGEN IN PERFUSED LIVERS 
 
Introduction 
In this chapter I take the parameters found to be optimal for CEST detection of 
glycogen in phantoms from Chapter IV, and apply them to isolated perfused livers, in an 
attempt to measure total hepatic glycogen content non-invasively. 
 
Methods 
The animals were studied under the purview of an Institutional Animal Care and Use 
Committee, and all applicable regulations and laws pertaining to the use of laboratory 
animals were followed.  The perfused liver procedure has been published in detail 
elsewhere (Cohen, 1987) and is summarized briefly here.  C57/BL6 mice (3-6 months 
old) were fed either normal chow or a high fructose diet (Research Diets Inc. #124908i) 
for 4-7 days to elevate liver glycogen (Koo, 2008).  Mice were anesthetized (Nembutal 
IP, 50 mg/kg) during the dark cycle.  Following a laparotomy, the portal vein was 
exposed and cannulated, and the liver was excised and perfused with a pre-oxygenated 
Krebs-Henseleit bicarbonate buffered solution.  The liver was then placed into a custom 
20 mm NMR tube and the entire assembly was placed inside the NMR spectrometer.  
31P MRS was initially performed to assess liver viability via ATP and Pi levels.  
Following manual shimming adjustments (typical water 1H linewidth = 30-50 Hz) and 
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centering of the water frequency, baseline 13C MRS and CEST Z-spectra were acquired 
and followed by the addition of glucagon (100 pM) to the perfusate to stimulate 
glycogen breakdown and thereby provide a range of liver glycogen values to be 
measured in a single study.  Interleaved 13C MRS and CEST acquisitions were then 
performed until liver glycogen reached a level near the 13C MRS detection limit, 
estimated to be ~50 μmoles.  This protocol is shown in Figure 10.  A total of 13 perfused 
liver studies were performed, with each study yielding 1-4 separate glycogen 
measurements (determined by the starting glycogen content, glycogen breakdown rate, 
and limit of detection). 
 
Figure 10. Interleaved CEST and 13C MRS protocol used in perfused liver measurements of 
total liver glycogen. 
 
Data analysis methods were identical to those already described in Chapter IV 
for the phantom studies, with the addition of computational simulations to estimate the 
inherent errors in each measurement method.  As each liver started with a different 
glycogen level, the calculation of uncertainties with repeated measures was not 
feasible.  As an alternative, I used Monte Carlo simulations based on the SNR of the 13C 
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and 1H spectra to generate standard deviations for each 13C MRS and CEST 
measurement, respectively.  For the 13C MRS errors, a normal distribution with a mean 
of zero and standard deviation equal to the root mean square (RMS) noise of the 13C 
MRS spectrum was created and random values from this distribution were added to 
each resonance.   The total sum of the areas of the glycogen MRS peaks was then 
recalculated and this procedure was repeated 50,000 times to generate a distribution of 
13C MRS signal areas.  The standard deviation of this distribution was used as the 
horizontal error bar in the plot of 13C MRS determined glycogen versus CEST MTRasym 
AUC.  For the CEST errors, a normal distribution with a mean of zero and a standard 
deviation equal to the RMS noise of the individual 1H MR spectra in the Z-spectrum was 
created and random values from this distribution were added to each resonance in the 
Z-spectrum.  The integral of each resonance in the new Z-spectrum was then re-
calculated and this new Z-spectrum was fit with an inverted Lorentzian model, from 
which the MTRasym AUC could be re-calculated as described in the Chapter IV.  This 
process was repeated 50,000 times to generate a distribution of MTRasym AUC  values 
and the standard deviation of this distribution was used as the vertical error bar in the 
plot of 13C MRS determined glycogen versus CEST MTRasym AUC. 
The correlation between 13C MRS determined glycogen and CEST MTRasym AUC 
was then investigated by randomly choosing pairs of 13C MRS determined glycogen 
values and CEST MTRasym AUC values from each distribution for all perfused liver 
studies, performing a linear regression, and repeating for all 50,000 values in the 
respective distributions.  In this way, distributions for the R2, slope, and Y-intercept 
values characterizing this correlation could be formed and the standard deviations of 
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each was used as an estimate of the error in each of these parameters.   This error 
simulation protocol is shown schematically in Figure 11. 
 
Figure 11. Monte Carlo simulation scheme to investigate the errors in the 13C MRS and CEST 
measures of glycogen, and in the correlation of the two.  
 
Results and Discussion 
Figures 12A and 12B show raw 13C NMR and CEST data, respectively, acquired 
in a selected perfused liver experiment.  Here WE can see that the 100 pM dose of 
glucagon stimulated glycogen breakdown and served to efficiently generate a range of 
liver glycogen values in a single study.  However since glucagon will also cause glucose 
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release from the liver, and since glucose hydroxyl protons have also been shown to 
have a CEST signal (van Zijl, 2012; Chan, 2012), there was likely to be additional CEST 
signal following glucagon administration.  To account for this, data from all the perfused 
liver studies were separated into two groups, those acquired before glucagon addition 
and those acquired after glucagon addition. 
 
Figure 12. 13C MRS (A) and CEST (B) data from a selected perfused liver study. 
 
I also investigated which region of the MTRasym curve would be optimal to use for 
correlation with the 13C MRS data by comparing the R2 value for the correlation between 
13C MRS determined glycogen and CEST MTRasym AUC as different regions of the 
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MTRasym curve were incorporated into the AUC calculation.  Figure 13 shows the 
dependence of this R2 value on which region of the MTRasym curve was integrated (for 
fixed integration range of +2 ppm).  Here we see that the region that produced the 
maximum R2 value is [0.5 – 2.5 ppm] which is consistent with the glycogen hydroxyl 
protons being reported to resonate at approximately 1.2 ppm downfield from water (van 
Zijl, 2012). 
 
Figure 13. The dependence of R2 for the 13C MRS-CEST correlation on which region of the 
MTRasym curve was used for the AUC calculation. 
 
Figure 14 shows a plot of 13C MRS determined glycogen versus CEST MTRasym 
AUC0.5-2.5 for data acquired before (blue) and after (red) glucagon.  The R2 values were 
0.88 ± 0.054 and 0.87 ± 0.040, the slope values were 0.0091 ± 0.00078 and 0.0082 ± 
0.00064, and the Y-intercept values were -0.50 ± 0.38 and 2.4 ± 0.21, respectively 
(mean ± SD).  Error bars for the data points in Figure 14 as well for the standard 
deviations for the reported correlation parameters were determined by Monte Carlo 
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simulations described in Methods.  I observed a strong linear relationship between 13C 
MRS determined glycogen and CEST MTRasym AUC0.5-2.5 both before and after glucagon 
treatment.  The slope of the relationship was similar in both groups as evidenced by the 
overlapping standard deviations.  This slope value can be used in future studies as a 
calibration factor between CEST MTRasym AUC0.5-2.5 and total perfused liver glycogen.  
The fact that the Y-intercept is within two standard deviations of zero (i.e. not 
statistically different from zero) in the data obtained before glucagon addition 
demonstrates that there are few competing endogenous CEST metabolites in this 
spectral region of the liver.  The increased Y-intercept value observed after glucagon 
addition is attributed to glucose release from the liver adding an additional CEST signal 
during this period of the experiment. 
 
Figure 14. Correlation of CEST MTRasym AUC0.5-2.5 and 13C MRS determined glycogen before 
(blue), and after (red) glucagon addition. 
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Interestingly, this glucose CEST signal is much higher than would have been 
predicted based on the expected perfusate glucose concentration of approximately 1 
mM in the NMR tube (determined by the perfusion flow rate and observed glycogen 
breakdown rate), and differences in numbers of exchangeable hydroxyl protons 
between glucose and glycogen.  I noted that while the linear relationship between total 
glycogen and CEST MTRasym that was observed in phantoms was preserved in the 
perfused liver studies, the overall magnitude of the MTRasym signal was reduced 
approximately by a factor of 4 in the perfused liver studies.  Factors which could 
account for this are the lower water relaxation (T1w) values in liver compared to in 
phantom solutions, differences in the molecular architecture of glycogen (e.g. branching 
patterns, number of tiers) in liver compared to in phantom solutions (oyster glycogen), 
and also the protein-bound nature of glycogen in tissue (Roach, 2012).  The latter could 
reduce the CEST effect either directly by removing exchangeable glycogen hydroxyl 
protons or by altering the relaxation properties of the glycogen hydroxyl protons.  This 
observation of reduced glycogen CEST signal in liver has two significant implications in 
the design of in vivo studies using CEST based measurements of tissue glycogen.  
Firstly, glycogen phantom solutions cannot be used to calibrate in vivo tissue glycogen 
measurements as is often done with the NMR detection of other 
metabolites/biomolecules.  Secondly, the competing CEST signal from glucose 
represents a much larger potential hurdle than originally anticipated in the translation of 
this measurement to an in vivo setting (where glucose is always present in the liver).  
For example, a typical range of values for liver glycogen is 100 – 400 mM, while 
circulating glucose is generally near 5 mM.  However, the 4-fold reduction of glycogen 
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signal in liver I observed combined with the approximate 2-fold reduction in 
exchangeable protons in glycogen suggests that in vivo, the glucose CEST signal can 
range from 10-40% of the glycogen CEST signal.  As such, care must be taken to 
maintain glucose as constant as possible throughout an in vivo study to allow for 
specific detection of changes in the glycogen CEST signal.  This implies that the use of 
CEST to measure absolute changes in liver glycogen in vivo would likely perform 
optimally with a glucose clamp protocol.  It should be noted, however, that these studies 
were performed at 11.7 T which is much higher than most clinical MRI scanners.  As 
such, it is possible that at lower fields where relaxation times are generally shorter, the 
amount of completing glucose CEST signal may be different.    
The error bars for the plot shown in Figure 14, along with the errors reported for 
the R2, slope, and Y-intercept values were determined by Monte Carlo simulations 
based on the respective SNR of the 13C MRS glycogen spectra and 1H Z-spectra.  
These error values allow us to estimate and compare the relative precision inherent to 
each approach.  Defining the relative precision as the ratio of the dynamic range to the 
average error for each technique, I estimate values of 10:1 and 80:1 for 13C MRS and 
CEST, respectively, implying that CEST is inherently ~8-fold more precise than natural 
abundance 13C MRS.  It is important to realize, however, that this calculation is based 
solely on the SNR of the original 1H and 13C spectra and it is likely that other 
experimental factors such as variations in shimming quality and variations in B1 pulse 
power from experiment to experiment could reduce the precision of the CEST 
measurement.  As a preliminary assessment of this, I studied a 40 mM glycogen 
phantom (prepared as described in Chapter IV) and measured the CEST MTRasym 
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under the following three conditions: (1) optimal shimming (1H line width = 40 Hz) with 
B1 = 4 μT, (2) suboptimal shimming (1H line width = 50 Hz) with B1 = 4 μT, (3) optimal 
shimming with B1 = 3.6 μT (i.e. a 10% error in the B1 pulse).  I found that case (2) 
produced an error in the CEST MTRasym of ~5 % while case (3) produced an error of 
~10%.  Both of these errors are larger than the SNR-based errors estimated by the 
Monte Carlo simulations (~1-2%), demonstrating that variations in experimental 
parameters are likely to be the dominant source of error in CEST measurements of liver 
glycogen.  In contrast, I routinely observe that errors in 13C NMR measurements of 
glycogen are relatively insensitive to small variations in shimming and other 
experimental parameters, and are dominated mostly by the inherently low SNR of the 
13C nucleus. 
 
Conclusion 
 These studies demonstrate that CEST can be used to measure total glycogen 
content in perfused livers and that CEST measurements of liver glycogen are inherently 
more precise than 13C MRS.  These studies also suggest that glucose may be a larger 
than anticipated confounding factor in the CEST detection of glycogen and that control 
over, or at least sampling of, glucose concentrations may be necessary for the 
translation of this approach in vivo.   
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CHAPTER VI 
CEST MEASUREMENTS OF HEPATIC GLYCOGEN SYNTHESIS IN PERFUSED 
LIVERS 
 
Introduction 
In the previous chapter, I demonstrated that CEST methods could be used to 
measure total liver glycogen content.  Here, I seek to apply this approach to the 
measurement of hepatic glycogen synthesis rates in perfused livers.  
 
Methods 
The same general perfused liver procedure as described in Chapter V was used 
with the addition of 15 mM [1-13C] glucose to the perfusate to be used as a substrate for 
glycogen synthesis.  The use of the 13C label also affords the ability to use interleaved 
13C MRS measurements as before, but now with increased sensitivity and decreased 
acquisition time.  The overall protocol for this is shown below in Figure 15. 
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 Figure 15. Protocol for measurement of glycogen synthesis rates in perfused livers using 13C 
MRS and CEST.   
 
As before, livers from lean non-fasted C57 mice were used and the experimental 
conditions were varied by adding known effectors of glycogen synthesis to generate a 
range of hepatic glycogen synthesis rates, and also to generate data for statistical 
power calculations.  In the first set of studies, livers were harvested from mice either in 
the middle of the light cycle (expected to have lower glycogen synthesis) or dark cycle 
(expected to have increased glycogen synthesis) and perfused with [1-13C] glucose 
alone, and also with 1mM fructose for mice taken during the dark cycle (expected to 
have further increased glycogen synthesis).  In the second set of studies, livers 
harvested from mice taken in the middle of the dark cycle were perfused with varying 
concentrations of glucagon which is expected to inhibit glycogen synthesis.     
 The data analysis methods were similar to those described in Chapter 5 except 
for the omission of Monte Carlo error simulations which were unnecessary due to the 
ability to use repeated trials under identical conditions.  13C spectral integrals were 
calculated for each time point and converted to absolute glycogen amounts using the 
calibration curve shown in Figure 9.  CEST Z-spectra and MTRasym curves were 
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calculated as before and numerically integrated from [0 – 6 ppm] and this MTRasym AUC 
was converted to an absolute glycogen amount using an analogous curve to that in 
Figure 14, determined now by integrating the MTRasym curve from [0 – 6 ppm] instead of 
[0.5 – 2.5 ppm] as in Chapter 5.  Subtraction of baseline signals resulted in plots of the 
increment in absolute amount of glycogen versus time for each measurement method, 
and the average slope of each was calculated to yield independent measures of 
glycogen synthesis in units of μmoles/min.  This protocol is shown for a selected study 
in Figure 16 below. 
Figure 16.  Data analysis protocol for the calculation of rates of glycogen synthesis from 13C 
MRS and CEST measurements. 
 
Results and Discussion 
Data from the first set of studies is shown in Figure 17 which demonstrates that 
1mM fructose increases glycogen synthesis, while harvesting the livers in the middle of 
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the light cycle decreases glycogen synthesis (two-factor ANOVA P < 0.0001, no 
difference between 13C MRS and CEST).  These data were then used to develop a 
power calculation to determine approximate samples sizes needed to detect changes in 
glycogen synthesis.  For this calculation, the following values were used:  mean value of 
glycogen synthesis = 0.55; average standard deviation = 0.2; expected change in 
glycogen synthesis with treatment = 0.3.  The results of this are shown in Table 1 for a 
two-sided analysis assuming a confidence level of α = 0.05. 
 
Figure 17.  CEST and 13C MRS measurements of glycogen synthesis rates for perfused livers 
with different starting conditions. 
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Power Level # of Studies (n) (n) 
0.7 3 
0.75 4 
0.8 (typically chosen) 4 
0.85 4 
0.9 5 
 
Table 1. Power calculation for sample size requirements to detect changes in glycogen 
synthesis rates with CEST based on data from Figure 17. 
 
The data from the glucagon titration is shown in Figure 18.  As expected, 
glucagon dose-dependently reduced glycogen synthesis and both the 3 pM and 10 pM 
were significantly different from no glucagon (0 pM), and also different from each other 
(two-factor ANOVA P < 0.0001, no difference between 13C MRS and CEST).  
 
Figure 18. The effects of glucagon on hepatic glycogen synthesis ex-vivo. 
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These two data sets confirm that CEST has sufficient sensitivity to detect 
physiologically relevant changes in glycogen synthesis.  Interestingly, the error bars 
(SEMs) for the CEST measurements tended to be larger than those for the 13C MRS 
measurements in these studies.  This is in contrast to what was observed in the 
previous set of studies described in Chapter V where total glycogen levels were 
measured.  This is likely due to two factors.  First, 13C labeled glucose was used here 
which enhanced the SNR of the glycogen NMR signal approximately 10-fold.  Second, 
the changes in the CEST signal due to glycogen synthesis were superimposed on top of 
an already large CEST signal from the 15mM glucose in the perfusate.  As 
demonstrated in Chapter 5, small variations in experimental parameters are likely to be 
the dominant source of error in CEST measurements, and since the overall CEST 
signal is larger in this set of studies, these experimental errors are larger than what 
would be expected due the CEST signal from glycogen alone.    
The correlation between the CEST and 13C MRS measurements of glycogen 
synthesis is shown in Figure 18.  The slope and Y-intercept of this relationship was 0.88 
+/- .31 and 0.042 +/- 0.16 (95% confidence intervals), respectively.  That the slope is 
close to unity and the Y-intercept is close to zero confirm that CEST can accurately 
measure glycogen synthesis rates.  The overall R2 value for this relationship is 0.65 
which is not as strong as that obtained in the measurements of total glycogen levels 
alone.  This is most likely due to the increased error in the CEST measurements as 
described above.  
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 Figure 19. Correlation of 13C MRS and CEST measurements of glycogen synthesis.  
 
Conclusion 
 These studies demonstrate that CEST can be used to measure glycogen 
synthesis rates in perfused livers and also can likely be used to detect changes in 
glycogen synthesis rates with a reasonable number of subjects (4-5) per group.  Errors 
in CEST measurements of glycogen synthesis are larger than those observed with 13C 
MRS, likely due to the large perfusate concentrations of glucose needed to stimulate 
glycogen synthesis. 
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CHAPTER VII 
EFFECTS OF AMPK ACTIVATION ON HEPATIC GLYCOGEN SYNTHESIS 
 
Introduction 
In the previous chapter, I demonstrated that CEST can be used to measure rates 
of glycogen synthesis in perfused livers, and that this technique has sufficient precision 
to detect physiologically relevant changes in these rates.  I now apply this methodology 
to investigate a novel pharmacological question, the effects of acute activation of AMPK 
on hepatic glycogen synthesis.  
 
AMPK Biology 
AMPK is currently one of the most actively investigated areas of both molecular 
biology and pharmacology.  Activation of AMPK (by various means) has been shown to 
have various effects in metabolic tissues, generally stimulating catabolic, ATP-
generating pathways while inhibiting anabolic, ATP-consuming pathways .  This is 
achieved by direct phosphorylation of regulatory proteins and also by indirect effects on 
gene expression.  For this reason, the enzyme had been colloquially called a 'metabolic 
master switch' (Winder, 1999).  A summary of the known effects of AMPK along with 
upstream effectors of its activity effects are shown in Figure 20 below. 
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   Figure 20. The influence of AMPK on various metabolic pathways. 
 
Despite a wealth of literature, there are still many challenges and caveats in our 
current knowledge of AMPK.  Firstly, the main pharmacological tool which has been 
employed to activate AMPK, 5-aminoimidazole-4-carboxyamide-riboside (AICAR), 
works by intracellular conversion to an AMP analog (zMP), and thus raises the effective 
AMP/ATP ratio rather than activating the AMPK enzyme directly.  AICAR has relatively 
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poor potency (in vitro studies typically use concentrations ~ 1mM) for AMPK activation, 
and has also been shown to stimulate GPase and inhibit fructose-1,6-bisphosphatase 
(Vincent, 1991; Longus, 2003).  The therapeutic effects of Metformin were initially 
thought to be mediated via AMPK (Zhou, 2001), however recent work has demonstrated 
that Metformin is still able to suppress glucose output in hepatocytes derived from 
AMPK and LKB1 (an upstream regulator of AMPK) KO mice (Foretz, 2010).  Secondly, 
many studies have manipulated AMPK activity via alterations in the initial state of the 
subjects, (e.g. fed vs. fasted rodents, exercised/contracted vs. rested muscle).  While 
the results of these efforts can be used to glean correlative changes between AMPK 
activity and enzyme/pathway effects, direct causality cannot be assumed as these initial 
alterations can certainly have many effects beyond AMPK alone.  Lastly, much of our 
knowledge of AMPK is derived from measured effects at the level of mRNA or protein 
expression.  While changes at this level may translate to changes in enzyme activity 
and pathway flux in vivo, a linear relationship is not necessarily guaranteed.  
 With respect to glycogen metabolism, AMPK has been demonstrated to 
phosphorylate, and therefore inhibit, both liver and muscle glycogen synthase in vitro 
(Bultot, 2012, Carling, 1989).  Paradoxically, however, it was recently demonstrated that 
activation of AMPK with AICAR resulted in increased skeletal muscle glycogen levels in 
mice (Hunter, 2011).  Further work using site-directed mutagenesis showed that the 
allosteric activation of glycogen synthase by G6P was required for this effect.  AMPK 
increases glucose transport in skeletal muscle but not in liver, and because skeletal 
muscle hexokinase has a very low Km compared to liver GK (~0.1mM vs. ~10mM, 
respectively), it is entirely possible that liver and muscle G6P levels may differ 
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significantly following AMPK activation.  This, in turn, may result in potentially very 
different GSase and GPase activities, and hence different rates of glycogen synthesis.  
This illustrates that changes in glycogen metabolism can be difficult to predict as they 
represent the integrated sum of many different effectors, and that methods for direct 
measurement of glycogen like 13C MRS or CEST are necessary to understand the 
dynamics of glycogen metabolism.  The goal of this portion was to investigate the acute 
effects of AMPK activation on hepatic glycogen synthesis. 
 
Description of Small Molecule AMPK Activator 
For these studies the compound MK8722 was chosen as an activator of AMPK.  
The structure of MK8722 is shown in below in Figure 21.  
 
 
 
Figure 21. Chemical structure of small molecule AMPK activator MK8722. 
 
The in vitro profile for MK8722 against all 12 isoforms of AMPK is shown in in 
Table 2 as EC50 values along with the maximal activation of the enzyme in parentheses.  
Of particular interest for these studies are isoforms 1 and 7 which are the primary liver 
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isoforms, and the low EC50 values of 1 and 2 nM, respectively, confirm excellent 
potency of this compound against these isoforms. 
 
Isoform Subunits Human Mouse Rhesus 
    EC50 nM (%act) 
AMPK1  α1β1γ1 1  (328%) 1  (447%) 1  (1209%) 
AMPK2 α1β1γ2 
 
2  (293%) 1  (963%) 
AMPK3 α1β1γ3 4  (1519%) 3  (678%) 1  (472%) 
AMPK4 α1β2γ1 51  (874%) 25  (529%) 27  (1058%) 
AMPK5 α1β2γ2 63  (440%) 22  (216%) 21  (668%) 
AMPK6 α1β2γ3 29 (849%) 20  (354%) 16  (588%) 
AMPK7 α2β1γ1 2  (518%) 1  (541%) 1  (587%) 
AMPK8 α2β1γ2 6  (625%) 2  (538%) 1  (407%) 
AMPK9 α2β1γ3 4  (2026%) 5  (2353%) 2  (540%) 
AMPK10 α2β2γ1 50  (293%) 34  (558%) 36  (357%) 
AMPK11 α2β2γ2 56  (240%) 28  (315%) 23  (254%) 
AMPK12 α2β2γ3 15  (2111%) 26  (2400%) 15  (625%) 
 
Table 2. In vitro potencies of AMPK activator MK8722 against all the isoforms of AMPK for 
different species. 
 
One of the proximal targets of AMPK is the enzyme acetyl CoA carboxylase 
(ACC) which is a key step in de novo lipogenesis (DNL), and the phosphorylation of 
ACC (pACC) has been widely used as an indicator of AMPK activation (i.e. target 
engagement).  Figure 22A shows that following a 10 mg/kg oral dose of MK8722, levels 
of liver pACC were elevated (Merck – unpublished data).  Analysis of plasma samples 
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from this study showed that levels of MK8722 were approximately 10 μM.  Data from a 
separate study examining the effects of MK8722 on DNL in primary hepatocytes is 
shown in Figure 22B and confirms that maximal effect of MK8722 is achieved at 
concentrations of approximately 10 μM (Merck – unpublished data).  Hence for the 
current perfused liver studies, a perfusate dose of 10 μM for MK8722 was chosen.    
 
Figure 22. Effects of MK8722 on pACC in vivo (A), and on DNL in vitro (B). 
 
Methods 
The overall perfused liver protocol used was similar to that described in Chapter 
VI.  Livers from lean C57 mice were harvested in the middle of the dark cycle and 
perfused with 15 mM [1-13C] glucose and either 10 μM MK8722 or 0.1% DMSO (the 
solvent used for making stock solution of MK8722).  Glycogen synthesis was then 
measured using interleaved 13C MRS and CEST methods as described in Chapter VI.  It 
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is important to note that the data shown in Figure 17 confirms that this approach and 
these conditions have the potential to show either an increase or decrease in glycogen 
synthesis and thus I have not biased the study towards any one particular effect. 
 
Results and Discussion 
The results of this study are shown in Figure 23.  Here we see again excellent 
agreement between the CEST and 13C MRS measurements, and that MK8722 acutely 
inhibits glycogen synthesis (two-factor ANOVA, P = 0.0003, no difference in 13C MRS 
and CEST).  Hepatic ATP levels were measured using 31P MRS at the beginning and 
end of the each study and MK8722 had no effect on these, indicating that effects on 
glycogen synthesis were unlikely to be due to toxicity.  In separate perfused liver studies 
performed at Merck, MK8722 at 10 μM was shown to acutely reduce hepatic DNL from 
13C-pyruvate, consistent with the primary hepatocyte data shown in Figure 22, and 
further confirming target engagement of AMPK at this perfusate concentration.  Taken 
together, these findings demonstrate that acute AMPK activation in liver reduces 
glycogen synthesis. 
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 Figure 23.  The acute effects of AMPK activation on hepatic glycogen synthesis as measured 
with CEST and 13C MRS. 
 
This is an interesting finding as it is the opposite effect as was reported in muscle 
(Hunter, 2011).  This is likely because while AMPK activation directly increases glucose 
uptake via GLUT4 translocation in muscle, no such effect is likely to be seen in liver as 
GLUT2 is embedded in the cell membrane and is not known to be directly affected by 
AMPK.  Thus, while in muscle the increased intracellular levels of glucose and G6P may 
override the inhibitory effects of AMPK on GSase, no such mechanism occurs in liver 
and the result is an inhibition of glycogen synthesis due to direct phosphorylation and 
inhibition of GSase by AMPK.  This finding is also consistent with other reports of 
associations between AMPK activation and reductions in hepatic glycogen synthesis 
observed in response to hepatic glycogen loading (Winnick, 2011) and elevated hepatic 
nitric oxide levels (An, 2010). 
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A reduction in glycogen synthesis is the opposite effect as seen with two other 
drug targets (GK activators and GP inhibitors) which are known to ameliorate 
hyperglycemia, at least in preclinical models.  While at first this suggests that hepatic 
AMPK activation may not have a favorable therapeutic effect for diabetes, it must be 
remembered that AMPK has been reported to have many other hepatic and extra-
hepatic effects which are likely to be beneficial such as reduction of fatty liver (Viollet, 
2006), increased muscle glucose uptake (Sakoda, 2002), and reduced hepatic 
gluconeogenesis (Viollet, 2006), although the latter still remains a topic of debate. 
   
Conclusion 
These studies demonstrate that acute activation of AMPK with MK8722 reduces 
hepatic glycogen synthesis.  This result also demonstrates that CEST measurements of 
glycogen synthesis rates are of sufficient precision to detect physiologically relevant 
changes in response to pharmacological effectors. 
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CHAPTER VIII 
PILOT CEST MRI IMAGING MEASUREMENTS OF GLYCOGEN SYNTHESIS IN VIVO 
AT 7T 
 
Introduction 
The good overall performance of CEST in terms of measuring both total glycogen 
content and glycogen synthesis rates described in the two previous chapters suggested 
that it may be possible to develop a protocol to measure glycogen synthesis rates in 
vivo.  I report here the preliminary results of this effort. 
 
Methods 
Phantom Studies – As a preliminary check that the CEST acquisition parameters 
used in the previous studies were appropriate for use at 7T, I prepared glycogen 
phantoms as described in Chapter IV at concentrations of 100 mM, 200 mM, and 400 
mM in 5 mm NMR tubes.  These were then arranged horizontally in a 7T Bruker MRI 
system and Z-images were acquired by using a RARE imaging sequence (parameters 
described in the next section) with CEST saturation pulses at offsets identical to those 
used in the previous perfused liver studies. 
MRI Acquisitions – For both the phantom and in vivo studies at 7T, a 30 mm 
quadrature volume coil was used in a Bruker 7T MRI equipped with Paravision 6.  After 
typical adjustments (tuning, shimming, pulse power calibrations), T1-weighted RARE 
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images were acquired initially to ensure appropriate placement in the coil.  CEST Z-
images were then acquired using a block saturation pulse (4 uT, 500 ms) in combination 
with a RARE imaging sequence (64 x 64 pixels, RARE factor = 32, centric encoding, 
TR/TE = 20 sec / 5 msec, total acquisition time ~ 20 min). 
Animal Protocol – Lean C57 mice were anesthetized in the middle of the light 
cycle with 3% isoflurane and a tail vein cannula was inserted and used to take a 
baseline blood glucose measurement.  Mice were then transferred to a heated holder 
and inserted into a Bruker 7T horizontal MRI equipped with a 30 mm volume coil and 
respiratory monitoring and localizer images combined with T1-weighted RARE images 
with coronal slices were used to position the liver at magnet center.  Respiratory-gated 
CEST acquisitions were then performed on a 2 mm slice encompassing as much liver 
as possible while remaining at a sufficient distance from the lungs and stomach.  
Saturation offsets were as follows: [12, 6, 3, 2, 1.75, 1.5, 1.25, 1, 0.75, 0.5, 0.4, 0.3, 
0.25, 0.2, 0.15, 0.1, 0.5, 0, 100 ppm] which resulted in a total acquisition time of 25 min.  
The additional saturation offsets were added around 0 ppm to allow for more accurate 
centering of the Z-spectrum over the slice.  The larger offset of the reference frequency 
(100 ppm) was due to the observation of overall reduction of signal intensity in the Z-
spectrum and as a result, the 40 ppm offset previously used no longer yielded the 
plateau value of the Z-spectrum.  I attribute this overall decrease in Z-spectrum intensity 
at higher frequency offsets to the increased amount of general magnetization transfer 
(MT) in vivo.  After an initial baseline CEST image was acquired, an I.V. infusion of [1-
13C] glucose consisting of a 1 g/kg bolus over 10 minutes followed by a 10 mg/kg/min 
slow infusion was administered via the tail vein.  This was accompanied by four 
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additional serial respiratory-gated CEST image acquisitions of ~25 min each.  The in 
vivo protocol is shown below in Figure 24. 
Figure 24.  Protocol for in vivo glycogen synthesis CEST studies. 
 
Data Analysis – Image processing was performed offline using Matlab functions.  
To accurately correct for variations in B0, additional saturation offsets were included 
around 0 ppm and the Z-spectrum for the following subset of saturation offsets was fit to 
an inverted Lorentzian model as described in Chapter IV to estimate the 0 ppm shift: 
[±0.4, ±0.3, ±0.25, ±0.2, ±0.15, ±0.1, ±0.05, 0, -0.5, -0.75, -0.1, -1.25, -1.5, -1.75, -2, -3 
ppm].  This procedure was chosen over performing a single field map or WASSR-type 
scan (Kim, 2009) at the beginning of the study because the B0 inhomogeneity may 
change over the course of a study and this current approach allows each Z-image to be 
corrected for 0 ppm variation independently.  The saturation offsets were then shifted 
and the Z-spectrum was corrected by linear interpolation.  This correction procedure is 
illustrated for a single Z-spectrum in Figure 25 below. 
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Figure 25.  Illustration of procedure used to correct for B0 inhomogeneity and variation in 0 ppm. 
 
Two different approaches were used to analyze the CEST image data.  In the 
first approach, analysis was performed on a region of interest (ROI) in the liver selected 
from the reference CEST image.  To calculate average glycogen synthesis rates, ROIs 
were drawn over the homogeneous portions of the CEST image and Z-spectra were 
constructed from the average intensities in the ROI.  Once corrected for any 0 ppm 
variation using the fitting procedure described above, the MTRasym function was 
calculated using the traditional method (eq.1) and was integrated over the region [0.5 – 
2.5 ppm] to yield an AUC value.  The baseline AUC value was then subtracted and a 
plot of ΔMTRasym versus time was constructed.  This process is shown for a sample 
study using two ROIs in Figure 26 below. 
63 
 
   
Figure 26. Illustration of the analysis method to calculate the change in the MTRasym AUC over 
time starting with two ROIs drawn on the CEST image. 
 
In the second analysis approach, calculations were performed on a pixel by pixel 
basis starting with the CEST Z-images.  Here, a 3D matrix (size = 64 x 64 x # of offsets) 
was  constructed corresponding to the individual CEST images acquired at various 
frequency offsets and the 0 ppm correction described above was applied to the Z-
spectrum from each pixel.  The MTRasym function and its AUC from [0.5 – 2.5] were then 
calculated for each pixel and finally, the slope of the MTRasym AUC versus time was 
calculated for each pixel.  This procedure is shown for a selected study in Figure 27 
below. 
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 Figure 27. Illustration of pixel by pixel analysis protocol.  The anatomical image (A) is used to 
locate different organs.  The 36 CEST Z-images (B) acquired at different frequency offsets are 
used to calculate each MTRasym AUC image (C).  The five MTRasym AUC images acquired over 
time were then used to calculate the slope image (D) which reflects glycogen synthesis.  Axes 
denote pixel number with a field of view of 50 mm for each image. 
 
Results and Discussion 
Phantom Studies – Data from the phantom studies is shown below in Figure 28.  
Panel (A) shows CEST images at +1 ppm and -1 ppm offsets.  Note that the difference 
in intensity is greatest for the 400 mM glycogen phantom and least for the 100 mM 
phantom.  Panel (B) shows the Z-spectrum for a circular ROI positioned on each 
phantom.  Panel (C) shows the MTRasym plot for the ROIs and panel (D) shows a plot of 
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MTRasym AUC versus glycogen concentration.  The high degree of linearity of this 
relationship confirms that the CEST acquisition parameters used are suitable for 
detection of glycogen in the physiological range.  
 
Figure 28. Data from glycogen phantom studies at 7T.  (A) CEST images for saturation offsets 
of +1 ppm and -1 ppm.  (B) Z-spectra corresponding to the ROIs in (A).  (C) MTRasym curves 
calculated from each Z-spectrum.  (D) Relationship of MTRasym AUC versus phantom glycogen 
concentration. 
 
In Vivo Studies – Figure 29 below shows a sample coronal respiratory gated T1-
weighted RARE image along with the CEST slice used for this subject and the 
corresponding axial image for this slice. 
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 Figure 29. Sample anatomical images and CEST slice used for this subject. 
 
Figure 30 below shows the blood glucose before and after the infusion protocol, 
confirming that the infusion raised the blood glucose level approximately 3-fold to a final 
value of ~450 mg/dl.  Previous perfused liver studies have shown that glycogen 
synthesis rates plateau at approximately 300-350 mg/dl, which suggests that glycogen 
synthesis was maximally activated throughout these studies. 
 
Figure 30. Blood glucose concentrations at the beginning and end of the glucose infusion 
protocol. 
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Figure 31 below shows a plot of average (n = 4) changes in MTRasym versus time 
using the first analysis protocol based on the average CEST signal intensities from 
RIOs in the liver.  Here WE see that, despite some variation in individual data points, 
the MTRasym still increases over time as would be expected with increasing glycogen 
levels.  The slope of this line is 0.011 MTRasym AUC/min. 
 
Figure 31. Average increase of MTRasym AUC0.5-2.5 over time in vivo. 
 
Sample results of the second analysis protocol using pixel by pixel calculations 
were shown in Figure 27, starting from the anatomical image through the CEST Z-
image, MTRasym AUC images, and the final slope image which reflects glycogen 
synthesis.  As a consistency check for this analysis method, three ROIs were selected 
for the slope image in each study, two for regions within the liver and one for the area of 
the spinal cord and paraspinal muscles.  The average slope was calculated for each 
68 
 
ROI and the results are shown below in Figure 32.  The average slope value of 0.0093 
MTRasym AUC/min for the liver regions is consistent with the slope value from Figure 31 
and is significantly different from values obtained from ROIs drawn around the region 
containing the spine and paraspinal muscles (P < 0.01, t-test). 
 
Figure 32.  Comparison of slope of the MTRasym AUC0.5-2.5 versus time for ROIs containing the 
liver or the spine and paraspinal muscles. 
 
While it is natural to attribute the observed increase in MTRasym solely to 
glycogen synthesis, it must be remembered that glucose is also elevated over the 
course of the study and thus could theoretically contribute to the increased MTRasym, 
especially since I have no knowledge of the circulating glucose time course profile over 
the study.  This appears to be unlikely, however, for three reasons.  First, since glucose 
in infused intravenously, circulating glucose should also be increased and the spine and 
paraspinal muscle regions, yet there is no increase CEST MTRasym over time in these 
regions (Figure 33).  Second, if glucose was responsible for the majority of the MTRasym 
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signal, then after the initial glucose bolus infusion (which is expected to increase 
glucose 2-3 fold, the total MTRasym should increase accordingly.  Looking at Figure 26, 
however, we see from T = -10 min to T = 50 min there is only a modest increase in the 
MTRasym.  Third, glucose has significant MTRasym signal at +3 ppm (van Zijl, 2007) while 
glycogen does not, and thus if responsible for the increase in MTRasym, we would expect 
to see a pronounced increase in the MTRasym at +3 ppm after the glucose bolus.  Figure 
26 again shows that this is not the case. 
 
Conclusion 
 The results of this chapter demonstrate that detection and MRI imaging of 
hepatic glycogen synthesis in vivo using CEST is feasible.  While there is much work 
that could to be done in terms of optimizing the image acquisition protocol (e.g. tighter 
sampling around 0 ppm to improve the correction, optimization of TR to reduce 
acquisition time and improve temporal resolution), these results lay the groundwork for 
future translation of this methodology  into larger animals and humans.   
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CHAPTER IX 
SUMMARY AND FUTURE DIRECTIONS 
 
In this work, I have addressed the question of whether CEST methods can be 
used to reliably measure hepatic glycogen levels and synthesis rates over the 
physiological range.  Using model glycogen solutions, I found that with appropriate 
choice of acquisition parameters, CEST measurements of total glycogen were linearly 
related to total phantom glycogen content.  Applying these same acquisition parameters 
to perfused livers treated ex-vivo with glucagon to generate a range of glycogen values 
in a single study, I then showed that CEST measures of total liver glycogen content 
were strongly correlated with interleaved 13C MRS measurements.  This demonstrated 
that CEST can reliably report glycogen content in a whole, functional liver.  Monte Carlo 
simulations of intrinsic errors in each method revealed that CEST was more precise 
than 13C MRS from an SNR standpoint, however it may be more susceptible to errors 
induced by variations in experimental parameters (e.g. shimming, B0 variation).   
I then adapted the perfused liver protocol to stimulate hepatic glycogen synthesis 
by adding high concentrations of [1-13C] glucose to the perfusate.  Under these 
conditions, and with the addition of effectors of hepatic glycogen synthesis (fructose, 
glucagon) to the perfusate, I found that the MTRasym AUC from serially acquired CEST 
spectra increased over time and this rate of increase was correlated with glycogen 
synthesis rates derived from interleaved 13C MRS measurements.  I also found that 
errors in CEST-derived measures of glycogen synthesis rates were larger than those 
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derived from 13C MRS measurements, though some of this was likely to be from the 
contaminating CEST signal from the high concentration of glucose in the perfusate.  
This finding was in contrast to what was observed in the measurements of total hepatic 
glycogen content, where CEST was shown to be inherently more precise. 
I then applied this platform for the measurement of glycogen synthesis rates to a 
novel pharmacological question, the effect of AMPK activation on hepatic glycogen 
synthesis.  Using a small molecule AMPK activator shown to be highly potent in vitro 
and to have good target engagement in vivo, I found that acute activation of AMPK 
inhibits hepatic glycogen synthesis, a result in contrast to a recently published finding in 
skeletal muscle.  This finding demonstrated that CEST measures of glycogen synthesis 
were of sufficient precision to detect changes in glycogen synthesis rates induced by a 
novel effector, and that glycogen metabolism is quite different in liver and muscle, and 
that changes in net glycogen synthesis cannot always be predicted from in vitro results 
alone.  An interesting follow up study would be to investigate hepatic glycogen synthesis 
rates after chronic treatment with the same AMPK activator in perfused livers from a 
mouse model of diabetes.  This would probe the question of whether the additional 
beneficial effects of long term AMPK activation (e.g. reduction of liver triglycerides, 
lowering of circulating glucose via increased skeletal muscle glucose uptake) have 
additional effects on hepatic glycogen metabolism beyond the acute effects resulting 
from the direct inhibition of GSase by AMPK. 
 After demonstrating that CEST could accurately measure glycogen synthesis 
rates in perfused livers, I then developed an in vivo protocol at 7T to stimulate hepatic 
glycogen synthesis using I.V. glucose infusions in anesthetized mice.  With appropriate 
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modifications to acquisition parameters to reflect the need for spatial correction of B0 
variation, I were able to show that the CEST MTRasym signal in liver regions increased 
over time during the glucose infusion, while the CEST MTRasym signal from regions 
containing the spine and surrounding paraspinal muscles did not.  This was 
demonstrated by two types of analysis, one on single Z-spectra derived from ROIs in 
the initial liver CEST image, and the other on ROIs in the liver after pixel by pixel 
calculation of MTRasym AUC and slope versus time. 
While measurement of total glycogen levels and glycogen synthesis rates in 
perfused livers has been well worked out in these studies, much more work is needed in 
the development of CEST based measures of glycogen metabolism in vivo.  One of the 
obvious shortcomings of our infusion protocol is the lack of knowledge of blood glucose 
concentrations between the start and end of the study.  This can be remedied by the 
use of surgically implanted sampling lines.  Currently, this is beyond our technical 
expertise due to the physical constraints of our 7T magnet room, however I 
acknowledge that future studies will eventually require this capability and a solution will 
need to be developed.     
In this work I increased hepatic glycogen synthesis in vivo with an IV glucose 
infusion, and observed a subsequent increase in the MTRasym signal over time.  An 
obvious next step would be to replace the glucose infusion with a glucagon infusion (or 
injection) to stimulate glycogen breakdown and then to attempt to measure that 
decrease in glycogen over time with CEST.  This would demonstrate that CEST can 
measure bidirectional changes in liver glycogen.  Additional studies could then modify 
the glucose infusion protocol by either adding fructose (to increase glycogen synthesis 
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further) or by systematically lowering the glucose infusion rate to yield different levels of 
hyperglycemia, and accordingly, different rates of glycogen synthesis.  This would 
address the precision of in vivo CEST measurements of glycogen synthesis and would 
allow for the use of power calculations to determine sample sizes required to detect 
certain changes in glycogen synthesis rates.  Interesting initial applications of this 
approach to pathology would be in cases of a known focal lesion in the liver, such as a 
tumor or cirrhosis.  As glycogen synthesis would likely be reduced in those regions, they 
would serve a positive control for known alterations in glycogen synthesis and could be 
used to assess the spatial sensitivity of this approach.  
Improvements in the CEST MRI acquisition parameters and analysis methods 
will also likely be required to maximize the utility of this approach and afford the highest 
probability of success for translation to larger species.  In these studies, I used very long 
TR values to ensure complete longitudinal relaxation.  This, however, results in long 
acquisition times (20-25 min/image) which can be problematic in large, free-breathing 
subjects, especially when multiple images need to be acquired over time to calculate a 
glycogen synthesis rate.  B0 inhomogeneity may also present issues when translating 
this approach to larger species.  I found that B0 generally varied by less than ±0.5 ppm 
over a mouse liver using a small (30 mm) volume coil.  The larger imaging coils required 
for use with larger subjects, however, may have more B0 variation.  While in theory this 
can always be accounted for by using the correction procedure described here, along 
with the addition of more saturation offsets over the expected range of B0 variation, this 
too could add significant time to each image acquisition. 
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In summary, this work expands upon the initial detection of the glycogen CEST 
signal, and lays the foundation for the use of CEST to probe glycogen metabolism in 
isolated tissues and in vivo.  While there are still hurdles, both known and possibly 
unknown, to overcome in the application of this methodology to larger species, I remain 
optimistic that these issues will be tractable, and that this approach will eventually yield 
a greater understanding of glycogen metabolism in both normal and pathological states.  
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APPENDIX  
 
A. Matlab Processing Code 
function l = CESTShiftLorentzian 
% l = CESTShiftLorentzian 
% CESTshiftLorentzian.m generates a string describing an upside down   
% Lorentzian lineshape for use in fitting CEST Z-Spectra, including a 
% shift term to correct for the centering of the spectra 
  
    h='x(1)'; 
    w='x(2)'; 
    dc='x(3)'; 
    xo='x(4)'; 
     
    l=strcat(dc,'-(',h,'./(4.*((xdata-',xo,')./',w,').^2 + 1))'); 
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function ppmList = WriteFreqList(BF,Zero,Flag,ppm1,ppm2,ppminc) 
% 
% ppmList = WriteFreqList(BF,Zero,ppm1,ppm2,ppminc) 
% 
% WriteFreqList.m writes a series of files containing frequency offsets 
% to be used by the Bruker AU program 'noemult' entitled CEST.1,  
% CEST.2, ..., CEST.n.  Freqency offsets are in +/- pairs (e.g. 5,-5,4,-
4,...) 
% These files are written to the C:\FreqLists\ directory which can then  
% be exported to XWin-NMR.  Input parameters are as follows: 
% 
%   BF = Basic Frequency (500.1300000 MHz) 
%   Zero = Frequency (MHz) corresponding to the water peak 
%   Flag = 1 if using the non-uniform offset list, Flag = 0 if using the  
%       uniformly spaced list 
%   ppm1 = starting ppm offset 
%   ppm2 = ending ppm offset 
%   ppminc = increment between ppm1 and ppm2  
  
if Flag==1; 
    % Make the non-uniformly spaced offset vector. 
    temp=[5 4 3.6 3.2 2.8 2.4 2 1.8 1.6 1.4 1.2 1 0.8 0.6 0.3]; 
    temp=[interleave(temp',-temp')' 0]; 
elseif Flag==2; 
    % Make the non-uniformly spaced 64 offset vector for future fitting. 
    temp=[9 8.75 8.5 8.25 8 7 6 5 4.5 4 3.5 3.25 3 2.8 2.6 2.4 2.2 2 1.8 ... 
          1.6 1.4 1.2 1 0.8 .7 .6 .5 .4 .3 .2 .1]; 
    temp=[interleave(temp',-temp')' 0]; 
elseif Flag==3; 
    % Make the non-uniformly spaced 32 offset vector for future fitting. 
    temp=[9 8.5 8 6 4 2.5 2 1.75 1.5 1.25 1 0.75 0.5 0.25 0.1]; 
    temp=[interleave(temp',-temp')' 0]; 
elseif Flag==4; 
    % Make the non-uniformly spaced 36 offset vector for 7T data. 
    temp=[20 10 5 2.5 2 1.75 1.5 1.25 1 0.75 0.5 0.4 0.3 0.2 0.15 0.1 0.05]; 
    temp=[interleave(temp',-temp')' 0]; 
elseif Flag==5; 
    % Make the non-uniformly spaced 36 offset vector for 7T data. 
    temp=[12 6 3 2 1.75 1.5 1.25 1 0.75 0.5 0.4 0.3 0.25 0.2 0.15 0.1 0.05]; 
    temp=[interleave(temp',-temp')' 0]; 
else 
    % Make the uniformly spaced offset vector. 
    a=[ppm1:-1*ppminc:ppm2]; 
    temp=zeros(size(a)); 
  
    % Arrange into +/- pairs. 
    for i=1:length(a)/2; 
        temp(2*i-1)=a(i); 
        temp(2*i)=a(length(a)-i+1); 
    end 
end 
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% Add on the reference offset. 
ppmList=[temp 40]'; 
b=1e6*(Zero-BF); 
  
% Convert ppm offsets into absolute frequencies. 
FreqList=b+ppmList*BF; 
  
% Write each offset into a sepate file. 
for i=1:length(FreqList); 
    filename=strcat('c:\Freqlists\CEST.',num2str(i)); 
    fid=fopen(filename,'w'); 
    fprintf(fid,'O '); 
    fprintf(fid,'%2.6f\n',BF); 
    fprintf(fid,'%2.2f',FreqList(i)); 
    fclose(fid); 
end 
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 function 
[FitZSpec,FitMTRasym,MTRasym,FitAUC,AUC,FitCESTdiff,CESTdiff]=MakeZSpec(expid
,expno,ppmList,si,sw,intLim,ppmTarget,FitFlag) 
  
% [ZSpec,FitMTRasym,MTRasym,FitAUC,AUC,FitCESTdiff,CESTdiff]= 
%            MakeZSpec(expid,expno,ppmList,si,sw,intLim,ppmTarget,FitFlag) 
% 
% MakeZSpec.m makes a Z-Spectrum from a '2rr' Bruker data file, i.e. a 
% file generated by packing the separate spectra in the Z-Spectrum into a  
% 2D data set.  This function also calculates the MTRasym two ways, (1)  
% directly from the Z-Spectrum (i.e. MTR = (S(-w)-S(w))/So, and (2) by  
% fitting the Z-Spectrum to an upside down Lorentzian and subtracting the 
% Z-Spectrum from the modeled Z-Spectrum.  Input parameters are as follows: 
% 
% expid - directory path and root file name 
% expno - experiment # from that series 
% ppmList - vector of ppm offset values used to make the Z-Spectrum  
% si - # of data points per individual spectrum (8192) 
% sw - Sweep width (Hz) of each spectrum (20) 
% intLim - region (+/-) to integrate the water peak over in each spectrum 
% ppmTarget - region of the MTRasym curve to integrate over for the final 
%   CEST measurement ([2.5 0.5]) 
% FitFlag = 1 to also perform the Lorentzian fit, FitFlag = 0 to not. 
% 
% Filenames are expected to be of the form <expid>.<expno> (e.g.  
% CESTStudy1.001, CESTStudy1.002, etc. for all the Z-Spectra 
  
% Manipulate the file path if necessary to parse out the filename. 
% Assumed to be of the form $PATH\expid.expno (e.g. C:\Data\Liver.001) 
filepath=''; 
a=find(expid=='\'); 
if isempty(a)==0; 
   filepath=expid(1:max(a)); 
   expid=expid(max(a)+1:length(expid)); 
end 
  
if expno<10; 
    expnostr=strcat('00',num2str(expno)); 
elseif expno>=10 & expno<100; 
    expnostr=strcat('0',num2str(expno)); 
else 
    expnostr=num2str(expno); 
end 
  
% Open the file and read the data. Note that the data comes out as one long 
% series of numbers (not a 2D array as Bruker would imply) which needs to be  
% chopped into the individual spectra in the next section. 
a=fopen(strcat(filepath,expid,'.',expnostr),'r','ieee-le'); 
spectra=fread(a,Inf,'int32');   
fclose(a); 
  
% Parse out the individual spectra into a matrix called 'specmat'. It is  
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% expected here that the ppm offsets are symmetric about 0 and that the  
% spectra have been acquired in an alternating fashion  
% (e.g. +9,-9,+8.5,-8.5,0.1,-0.1,...,0,RefFreq).  Examples noted in the  
% comments below will be for 32 ppm offsets. 
  
Nspecs=length(spectra)/si;  % Total # of spectra = 32 
for i=1:Nspecs/2;           % i=1:16 
                                                    % i=1, 1:si 
    specmat(i,:)=spectra(2*(i-1)*si+1:(2*i-1)*si);  % i=2, 2*si+1:3*si  
                                                    % i=16, 30*si+1:31*si 
  
                            % So temp(1:16) equals the positive offset 
    temp(i)=ppmList(2*i-1); % entries 1,3,5,...,31 in ppmList (#31 being 0) 
end 
  
for i=1:Nspecs/2-1;         % i=1:15 
                                                      % i=1, si+1:2*si 
    specmat(Nspecs-i,:)=spectra((2*i-1)*si+1:2*i*si); % i=2, 3*si+1:4*si 
                                                      % i=15, 29*si+1:30*si 
                             
                                 % So temp(31:-1:17) equals the negative 
    temp(Nspecs-i)=ppmList(2*i); % entries 2,4,6,...,30 in ppmList. 
end 
specmat(Nspecs,:)=spectra((Nspecs-1)*si+1:Nspecs*si); % i=32, 31*si+1:32*si 
temp(Nspecs)=ppmList(Nspecs); % So temp(32)=ppmList(32), the reference spec 
  
ppmList=temp'; % ppmList is now ordered correctly, e.g. 9,8.5,...0,...,-
8.5,9,Ref 
  
% Make the Z-Spectrum based on AUC from each spectrum. 
  
                       % In case you only want to use part of the spectrum 
if exist('intLim')==1; % to calculate the AUC, like when there's a large 
                       % lipid signal.  intLim has units of ppm.  
  
    limit1=round(si/2-intLim*si/sw); % Round the ppm limits to the nearest 
    limit2=round(si/2+intLim*si/sw); % data point 
     
    ZSpec=trapz(specmat(:,limit1:limit2),2); % Calculate the AUC 
else 
    ZSpec=trapz(specmat,2); % Calculate the AUC (no integration limits) 
end 
  
ZSpec=100*ZSpec/ZSpec(length(ZSpec)); % Normalize the Z-Spectrum to the 
                                      % reference spectrum 
                                       
  
% Make the MTRasym based on the Z-Spectrum. 
ppms=ppmList(1:length(ppmList)/2); % Picks out the first half (16) of the 
values 
MTRasym=zeros(length(ZSpec)/2,1); % (32) 
ZSpec=ZSpec(1:length(ZSpec)-1); % Removes the value from reference spectrum 
(31) 
for i=1:(length(ZSpec)-1)/2; % i=1:15 
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                                                      % The MTRasym 
calculation 
                                                      % i=1:ZSpec(31)-
ZSpec(1) 
    MTRasym(i)=ZSpec(length(ZSpec)-i+1)-ZSpec(i);     % i=2:ZSpec(30)-
ZSpec(2) 
                                                      %          | 
                                                      % i=15:ZSpec(17)-
ZSpec(15)     
end                                                   % Note still 0 at end. 
  
AUC=trapz(MTRasym) 
AUC=-trapz(ppms,MTRasym); % Total MTRasym AUC.  Note the negative since the  
                          % ppm values decrease 
  
% Plot the spectral series 
for i=1:Nspecs; 
   figure(10); 
   plot([(i-1)*si+1:i*si],specmat(i,:)) 
   hold on 
end 
   
% Plot the Z-Spectrum and MTRasym 
ppmList=ppmList(1:length(ppmList)-1); % (31) 
figure(1)   
plot(ppmList,ZSpec,'k') 
hold on 
plot(ppmList(1:length(MTRasym)),MTRasym,'k')     
set(gca,'XDir','Reverse') 
  
% Now calculate a more 'local' MTRasym value, either the value at the 
% expected offest, or in the region around the expected offest. 
  
                            % ppmTarget is either the value of the expected 
if prod(size(ppmTarget))>1; % max CEST effect or a range [min max] around 
                            % that expected value. 
                             
    adiff=find(ppmList-ppmTarget(1)==min(abs(ppmList-ppmTarget(1))));         
    bdiff=find(ppmList-ppmTarget(2)==min(abs(ppmList-ppmTarget(2))));     
    CESTdiff=-trapz(ppms(adiff:bdiff),MTRasym(adiff:bdiff)) 
else 
    adiff=find(ppmList-ppmTarget==min(abs(ppmList-ppmTarget))); 
    CESTdiff=MTRasym(adiff); 
end 
  
% If required, calculate the MTRasym by fitting to a Lorentzian, which is  
% described by its height, width, offset from 0, and asymptotic value 
  
if FitFlag==1; % Determines if a fit is to be done 
  
    % Defines the region over which to use the data to fit. This is 
    % generally far from 0 and close to 0. 
    FitRegion=[find(ppmList>=8)' find(ppmList<0.4 & ppmList>-2)' 
find(ppmList<=-8)']; 
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    % Calculate the initial parameters to use for the fit 
    dc0=ZSpec(1); 
    Zero=find(ppmList==0); 
    Height0=dc0-ZSpec(Zero); 
    a=find(ZSpec<Height0/2); 
    a=a(1); 
    Width0=2*abs(ppmList(a)); 
     
    % Define the data needed for the lsqcurvefit function 
    xdata=ppmList(FitRegion); 
    ydata=ZSpec(FitRegion); 
     
                            % Calls the script to generate the string  
    l=CESTShiftLorentzian;  % describing the upside-down Lorentzian which  
                            % is used for the fit. 
                     
    fiteqn=inline(l,'x','xdata'); 
    p0=[Height0 Width0 dc0 0]; % The initial parameters. 
    opts=optimset('MaxIter',100,'MaxFunEvals',2000); % Parameters used by 
                                                     % the fitting routine  
     
    % Performs the curve fit 
    
[param,ressum,residual,exitflag,output]=lsqcurvefit(fiteqn,p0,xdata,ydata,[],
[],opts); 
  
    % Extract the values of the parameters from the curve fit 
    param 
    Height=param(1); 
    Width=param(2); 
    dc=param(3); 
    xo=param(4); 
  
    % Plot the fit Z-Spectrum along with the data points used to fit 
    FitZSpec=dc-(Height./(4*((ppmList-xo)/Width).^2+1)); 
    plot(ppmList,FitZSpec,'r') 
    plot(xdata,ydata,'r*') 
     
    % Calculate the MTRasym from the modeled Z-Spectrum  
    FitMTRasym=FitZSpec-ZSpec; 
    FitMTRasym=FitMTRasym(1:length(MTRasym)); 
    plot(ppmList(1:length(MTRasym)),FitMTRasym,'r') 
    FitAUC=-trapz(ppms,FitMTRasym) 
    FitCESTdiff=-trapz(ppms(adiff:bdiff),FitMTRasym(adiff:bdiff)) 
    set(gca,'XDir','Reverse')    
    
end 
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 function 
C13Stdev=Make13CError(expid,expno,Areas,Heights,P2PNoise,n,GlycogenCalibratio
n) 
% 
%   C13AreaDist=Make13CError(Areas,Heights,P2PNoise,n) 
%   Make13CError uses a Monte Carlo approach to generate an estimate of the 
%   error from fitting a series of peaks in a 13C NMR spectrum.  This 
%   assumes that the spectrum has already been fit and the model peak areas 
%   and heights are known.  These are either read into the function directly 
%   or loaded from existing files. Input parameters are as follows: 
% 
%   Areas = list of peak areas for a given spectrum (use [] if already 
%       saved in a local file 
%   Heights = list of peak heights for a given spectrum (use [] if already 
%       saved in a local file 
%   LW = list of linewidths corresnpoding to each area 
%   P2PNoise = The peak to peak noise from the spectrum of intrest 
%   n = number of simulations to use (>10000 suggested) 
  
% Check if Areas and Heights are defined and load the files if not. 
if isempty(Areas)==1; 
    load(strcat(expid,'Areas0',num2str(expno),'.mat')) 
    load(strcat(expid,'Heights0',num2str(expno),'.mat')) 
end 
  
RMSNoise=P2PNoise/(2*sqrt(2)); % Calculate RMS noise from peak to peak noise 
C13AreaDist=zeros(n,length(Areas)); 
for i=1:length(Areas);                                      % The normalized 
    NormError=(Heights(i)+RMSNoise*randn(n,1))/Heights(i);  % error for each 
peak 
    C13AreaDist(:,i)=Areas(i)*NormError; % The distribution of areas for each 
peak 
end 
C13AreaDist=sum(C13AreaDist,2)*GlycogenCalibration; % The distribution of 
total glycogen values 
C13Stdev=std(C13AreaDist) 
mean(C13AreaDist) % Display the mean just to check that it is the same as the  
                  % original area value  
  
% Save the Areas and Heights so that they don't need to be looked up again                   
save(strcat(expid,'Areas0',num2str(expno),'.mat'),'Areas') 
save(strcat(expid,'Heights0',num2str(expno),'.mat'),'Heights') 
  
% Save the distribution for future use 
save(strcat(expid,'13CDist0',num2str(expno),'.mat'),'C13AreaDist') 
                  
% Plot the distribution 
figure(1) 
edges=(min(C13AreaDist):(max(C13AreaDist)-
min(C13AreaDist))/50:max(C13AreaDist)); 
bar(edges,histc(C13AreaDist,edges)); 
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 function 
[Average,Stdev]=ZSpecError(expid,expno,ppmList,si,sw,intLim,ppmTarget,P2PNois
e,n) 
% 
[Average,Stdev]=ZSpecError(expid,expno,ppmList,si,sw,intLim,ppmTarget,P2PNois
e,n) 
%  
% ZSpecError.m uses a Monte Carlo approach to generate an error estimate  
% of the MTRasym derived from a given Z-Spectrum.  The beginning part 
% of the program reads in the file and parses out the individual spectra 
% much like MakeZSpec.m.  Then once the Z-Spectrum is calculated, some  
% random error defined by the peak to peak noise is added to each point in  
% the spectrum and the resulting Z-Spectrum is analyzed to calculate the  
% new MTRasym curve.  This is repeated n times to form a distribution of  
% MTRasym curves.  Input parameters are as follows: 
% 
% expid - directory path and root file name 
% expno - experiment # from that series 
% ppmList - vector of ppm offset values used to make the Z-Spectrum  
% si - # of data points per individual spectrum (8192) 
% sw - Sweep width (Hz) of each spectrum (20) 
% intLim - region (+/-) to integrate the water peak over in each spectrum (2) 
% ppmTarget - region of the MTRasym curve to integrate over for the final 
%   CEST measurement ([2.5 0.5]) 
% P2PNoise = Peak to peak noise from the spectra making up the Z-Spectrum 
(2e3) 
% n - number of times to run the simulation (5000 - 50000) 
  
% Manipulate the file path if necessary to parse out the filename. 
% Assumed to be of the form $PATH\<expid>.<expno> (e.g. C:\Data\Liver.001) 
filepath=''; 
a=find(expid=='\'); 
if isempty(a)==0; 
   filepath=expid(1:max(a)); 
   expid=expid(max(a)+1:length(expid)); 
end 
  
if expno<10; 
    expnostr=strcat('00',num2str(expno)); 
elseif expno>=10 & expno<100; 
    expnostr=strcat('0',num2str(expno)); 
else 
    expnostr=num2str(expno); 
end 
  
% Open the file and read the data. Note that the data comes out as one long 
% series of numbers which needs to be chopped into the individual spectra 
% in the next section. 
a=fopen(strcat(filepath,expid,'.',expnostr),'r','ieee-le'); 
spectra=fread(a,Inf,'int32');   
fclose(a); 
  
% Parse out the individual spectra. It is expected here that the ppm 
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% offsets are symmetric about 0 and that the spectra have been acquired in 
% an alternating fashion (e.g. +9,-9,+8.5,-8.5,...,0,RefFreq).  Examples 
% noted in the comments below will be for 32 ppm offsets. 
  
Nspecs=length(spectra)/si;  % Total # of spectra = 32 
for i=1:Nspecs/2;           % i=1:16 
                                                    % i=1, 1:si 
    specmat(i,:)=spectra(2*(i-1)*si+1:(2*i-1)*si);  % i=2, 2*si+1:3*si  
                                                    % i=16, 30*si+1:31*si 
  
                            % So temp(1:16) equals the positive offset 
    temp(i)=ppmList(2*i-1); % entries 1,3,5,...,31 in ppmList (#31 being 0) 
end 
  
for i=1:Nspecs/2-1;         % i=1:15 
                                                      % i=1, si+1:2*si 
    specmat(Nspecs-i,:)=spectra((2*i-1)*si+1:2*i*si); % i=2, 3*si+1:4*si 
                                                      % i=15, 29*si+1:30*si 
                             
                                 % So temp(31:-1:17) equals the negative 
    temp(Nspecs-i)=ppmList(2*i); % entries 2,4,6,...,30 in ppmList. 
end 
specmat(Nspecs,:)=spectra((Nspecs-1)*si+1:Nspecs*si); % i=32, 31*si+1:32*si 
temp(Nspecs)=ppmList(Nspecs); % So temp(32)=ppmList(32), the reference spec 
  
ppmList=temp'; % ppmList is now ordered correctly, e.g. 9,8.5,...0,...,-8.5,-
9,Ref 
  
% Make the Z-Spectrum based on AUC from each spectrum. 
  
                       % In case you only want to use part of the spectrum 
if exist('intLim')==1; % to calculate the AUC, like when there's a large 
                       % lipid signal.  intLim has units of ppm.  
  
    limit1=round(si/2-intLim*si/sw); % Round the ppm limits to the nearest 
    limit2=round(si/2+intLim*si/sw); % data point 
     
    ZSpecOriginal=trapz(specmat(:,limit1:limit2),2); % Calculate the AUC for 
each spectrum 
    PeakHeights=max(specmat,[],2); % Finds the peak heights for error 
analysis later 
else 
    ZSpecOriginal=trapz(specmat,2); % Calculate the AUC (no integration 
limits) 
    PeakHeights=max(specmat,[],2); 
end 
  
ZSpec0=100*ZSpecOriginal/ZSpecOriginal(length(ZSpecOriginal)); % Normalize 
the Z-Spectrum to the 
                                                              % reference 
spectrum 
  
% Make the original MTRasym based on the Z-Spectrum. 
ppms=ppmList(1:length(ppmList)/2); % Picks out the first half (16) of the 
values 
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MTRasym0=zeros(length(ZSpec0)/2,1); % Allocates 16 values 
ZSpec0=ZSpec0(1:length(ZSpec0)-1); % Removes the value from reference 
spectrum 
for i=1:(length(ZSpec0)-1)/2; % i=1:15 
                                                      % The MTRasym 
calculation 
                                                      % i=1:ZSpec(31)-
ZSpec(1) 
    MTRasym0(i)=ZSpec0(length(ZSpec0)-i+1)-ZSpec0(i); % i=2:ZSpec(30)-
ZSpec(2) 
                                                      %          | 
                                                      % i=15:ZSpec(17)-
ZSpec(15)     
end                                                   % Note still 0 at end. 
  
% Plot the Z-Spectrum and MTRasym 
ppmList=ppmList(1:length(ppmList)-1); % Removes the reference offset value 
figure(1)   
plot(ppmList,ZSpec0,'k') 
hold on 
plot(ppmList(1:length(MTRasym0)),MTRasym0,'k')     
set(gca,'XDir','Reverse') 
  
% Up until now this has all been the same as in MakeZSpec.m.  Now we will 
% incorporate some error into each value in the Z-Spectrum.  This is done 
% by adding a random # based on the spectral noise to each value in the 
% Z-Spectrum.  This will be done n times. 
  
% First define the region of the MTRasym curve over which to calculate the  
% AUC before the loop for efficiency. 
  
                            % ppmTarget is either the value of the expected 
if prod(size(ppmTarget))>1; % max CEST effect or a range [max min] around 
                            % that expected value. 
                             
    adiff=find(ppmList-ppmTarget(1)==min(abs(ppmList-ppmTarget(1))));         
    bdiff=find(ppmList-ppmTarget(2)==min(abs(ppmList-ppmTarget(2))));     
else 
    adiff=find(ppmList-ppmTarget==min(abs(ppmList-ppmTarget))); 
end 
  
% Here's the main loop for the Monte Carlo error simulations 
tstart=tic; 
RMSNoise=P2PNoise/(2*sqrt(2)); 
for i=1:n;                       
                                                                 % Add random 
error 
    PeakError=PeakHeights+RMSNoise*randn(length(PeakHeights),1); % to the 
peak 
                                                                 % heights 
based on  
                                                                 % the P2P 
noise 
    NormError=PeakError./PeakHeights; % Normalized error of each peak 
    ZSpecNew=ZSpecOriginal.*NormError; % This is the Z-Spectrum + error at 
each point 
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    ZSpecNew=100*ZSpecNew/ZSpecNew(length(ZSpecNew)); % Normalize the Z-
Spectrum to the 
                                          % reference spectrum 
  
    ZSpecNew=ZSpecNew(1:length(ZSpecNew)-1); % Removes the value from 
reference spectrum    
  
    % Defines the region over which to use the data to fit. This is 
    % generally far from 0 and close to 0. 
    FitRegion=[find(ppmList==8)' find(ppmList<0.4 & ppmList>-2)' 
find(ppmList==-8)']; 
     
    % Calculate the MTRasym by fitting to a Lorentzian, which is described 
    % by its height, width, offset from 0, and asymptotic value. 
  
    dc0=ZSpecNew(1);                % 
    Zero=find(ppmList==0);          % Calculates the  
    Height0=dc0-ZSpecNew(Zero);     % initial parameters  
    a=find(ZSpecNew<Height0/2);     % to be used  
    a=a(1);                         % in the fit 
    Width0=2*abs(ppmList(a));       %     
     
    % Define the data needed for the lsqcurvefit function 
    xdata=ppmList(FitRegion); 
    ydata=ZSpecNew(FitRegion); 
    l=CESTShiftLorentzian; % the upside-down Lorentzian which is used for the 
fit 
                     
    fiteqn=inline(l,'x','xdata'); 
    p0=[Height0 Width0 dc0 0]; % The initial parameters. 
    opts=optimset('MaxIter',100,'MaxFunEvals',2000,'Display','off'); % 
Parameters used by 
                                                                     % the 
fitting routine  
    % Performs the curve fit 
    
[param,ressum,residual,exitflag,output]=lsqcurvefit(fiteqn,p0,xdata,ydata,[],
[],opts); 
  
    % Extract the values of the parameters from the curve fit 
    Height=param(1); 
    Width=param(2); 
    dc=param(3); 
    xo=param(4); 
  
    % Plot the fit Z-Spectrum along with the data points used to fit 
    FitZSpec=dc-(Height./(4*((ppmList-xo)/Width).^2+1)); % The Lorentzian 
equation 
    plot(ppmList,FitZSpec,'r') 
    plot(xdata,ydata,'r*') 
     
    % Calculate the MTRasym from the modeled Z-Spectrum  
    FitMTRasym=FitZSpec-ZSpecNew; 
    FitMTRasym=FitMTRasym(1:length(ZSpecOriginal)/2); 
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    % Plot the many MTRasym curves 
    plot(ppmList(1:length(FitMTRasym)),FitMTRasym,'r') 
    set(gca,'XDir','Reverse')    
     
    % Calculate the AUC under the defined region 
    FitMTRAUC(i)=-trapz(ppms(adiff:bdiff),FitMTRasym(adiff:bdiff)); 
end 
toc(tstart) 
  
% Calculate the statistics for the distribution of MTRasym AUC values 
Average=mean(FitMTRAUC) 
Stdev=std(FitMTRAUC) 
strcat(filepath,expid,'Dist00',num2str(expno),'.mat') 
save(strcat(filepath,expid,'Dist00',num2str(expno),'.mat'),'FitMTRAUC') 
  
% Plot the distribution 
figure(2) 
edges=(min(FitMTRAUC):(max(FitMTRAUC)-min(FitMTRAUC))/50:max(FitMTRAUC)); 
bar(edges,histc(FitMTRAUC,edges)); 
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 function Stdev=CESTvsC13Correlation(n) 
  
% This function generates the distribution of the parameters descrining the 
% correlation between CEST and 13C data. 
  
a1=load('c:\FreqLists\KWCESTLiver7Dist001.mat'); 
a2=load('c:\FreqLists\KWCESTLiver7Dist002.mat'); 
a3=load('c:\FreqLists\KWCESTLiver8Dist001.mat'); 
a4=load('c:\FreqLists\KWCESTLiver10Dist001.mat'); 
a5=load('c:\FreqLists\KWCESTLiver13Dist001.mat'); 
a6=load('c:\FreqLists\KWCESTLiver14Dist001.mat'); 
a7=load('c:\FreqLists\KWCESTLiver15Dist001.mat'); 
a8=load('c:\FreqLists\KWCESTLiver16Dist001.mat'); 
a9=load('c:\FreqLists\KWCESTLiver18Dist001.mat'); 
a10=load('c:\FreqLists\KWCESTLiver18Dist002.mat'); 
a11=load('c:\FreqLists\KWCESTLiver20Dist001.mat'); 
a12=load('c:\FreqLists\KWCESTLiver23Dist001.mat'); 
a13=load('c:\FreqLists\KWCESTLiver23Dist002.mat'); 
  
b1=load('c:\FreqLists\KWCESTLiver713CDist023.mat'); 
b2=load('c:\FreqLists\KWCESTLiver713CDist034.mat'); 
b3=load('c:\FreqLists\KWCESTLiver813CDist023.mat'); 
b4=load('c:\FreqLists\KWCESTLiver1013CDist023.mat'); 
b5=load('c:\FreqLists\KWCESTLiver1313CDist023.mat'); 
b6=load('c:\FreqLists\KWCESTLiver1413CDist023.mat'); 
b7=load('c:\FreqLists\KWCESTLiver1513CDist023.mat'); 
b8=load('c:\FreqLists\KWCESTLiver1613CDist023.mat'); 
b9=load('c:\FreqLists\KWCESTLiver1813CDist023.mat'); 
b10=load('c:\FreqLists\KWCESTLiver1813CDist034.mat'); 
b11=load('c:\FreqLists\KWCESTLiver2013CDist023.mat'); 
b12=load('c:\FreqLists\KWCESTLiver2313CDist023.mat'); 
b13=load('c:\FreqLists\KWCESTLiver2313CDist034.mat'); 
  
for i=1:n; 
    for j=1:13; 
        
%['y(',num2str(j),')=',strcat('a',num2str(j),'.FitMTRAUC(',num2str(i),');')] 
        
%['x(',num2str(j),')=',strcat('b',num2str(j),'.C13AreaDist(',num2str(i),');')
] 
        
eval(['y(',num2str(j),')=',strcat('a',num2str(j),'.FitMTRAUC(',num2str(i),');
')]); 
        
eval(['x(',num2str(j),')=',strcat('b',num2str(j),'.C13AreaDist(',num2str(i),'
);')]); 
    end 
    figure(1) 
    plot(x,y,'*') 
    hold on 
    p=polyfit(x,y,1); 
    slope(i)=p(1); 
    intercept(i)=p(2); 
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    yfit=polyval(p,x); 
    yresid=y-yfit; 
    SSresid=sum(yresid.^2); 
    SStotal=(length(y)-1)*var(y); 
    rsq(i)=1-SSresid/SStotal; 
end 
xlabel('13C NMR Glycogen (umoles)') 
ylabel('MTRasym AUC 0.5 --> 2.5 ppm')  
  
mean(rsq) 
Stdev=std(rsq) 
figure(2) 
edges=(min(rsq):(max(rsq)-min(rsq))/50:max(rsq)); 
bar(edges,histc(rsq,edges)); 
xlabel('R-Squared') 
  
mean(slope) 
Stdev=std(slope) 
figure(3) 
edges=(min(slope):(max(slope)-min(slope))/50:max(slope)); 
bar(edges,histc(slope,edges)); 
xlabel('Slope') 
  
mean(intercept) 
Stdev=std(intercept) 
figure(4) 
edges=(min(intercept):(max(intercept)-min(intercept))/50:max(intercept)); 
bar(edges,histc(intercept,edges)); 
xlabel('Y-Intercept') 
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 function Z = LoadZImage(m,n,nfiles) 
% 
% Z = LoadZImage(m,n,nfiles) 
% 
% LoadZImage loads DICOM images (m by n pixels in each, nfiles = # of images) 
% in the current directory and forms a 3D matrix where each 'slice'  
% is a different saturation frequency offset. 
  
Z=zeros(m,n,nfiles); 
for i=1:nfiles; 
    if i<10; 
        file=strcat('MRIm0',num2str(i),'.dcm'); 
        Z(:,:,i)=dicomread(file); 
    else 
        file=strcat('MRIm',num2str(i),'.dcm'); 
        Z(:,:,i)=dicomread(file); 
    end 
end 
  
Z=double(Z); 
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 function 
[MTRasym,MTRasymCorr,AUC,AUCCorr,CESTdiff,CESTdiffCorr]=MakeCorrectedMTRasym(
ppmList,ZSpec,ppmTarget,Center) 
  
% [MTRasym,MTRasymCorr,AUC,AUCCorr,CESTdiff,CESTdiffCorr]= 
%                                 
MakeCorrectedMTRasym(ppmList,ZSpec,ppmTarget,Center) 
% 
% MakeCorrectedMTRasym.m calculates the MTRasym function from a Z-spectrum in 
two 
% ways, (1) directly from the Z-Spectrum (i.e. MTR = (S(-w)-S(w))/So,  
% and (2) by correcting for any offset from 0 ppm.  This is done by  
% fitting the middle region of the Z-Spectrum to an upside down Lorentzian 
and  
% using that fit to find the 'true' zero.  The ppm axis is then shifted and 
% the Z-Spectrum values are corrected by linear interpolation   
% Input parameters are as follows: 
  
% ppmList - vector of ppm offset values used to make the Z-Spectrum  
% ZSpec - the Z-spectrum values corresponding to each value in ppmList 
% ppmTarget - region of the MTRasym curve to integrate over for the final 
%   CEST measurement (e.g. [6 0] [2.5 0.5]) 
% Center - the loaction of the middle of the Z-Spectrum (generally this is 
%   found by the Lorentzian fit but may in some cases be known  
  
  
% Re-order the ppmList and ZSpec values as it is expected here that the  
% ppm offsets are symmetric about 0 and that the spectra have been  
% acquired in an alternating fashion (e.g. +12,-12,+6,-6,...,0.1,-
0.1,0,RefFreq). 
% Examples noted in the comments below will be for 32 ppm offsets. 
  
Nspecs=length(ZSpec);  % Total # of spectra = 32 
for i=1:Nspecs/2;      % i=1:16 
  
    Ztemp(i)=ZSpec(2*i-1); % So temp(1:16) equals the positive offset 
    temp(i)=ppmList(2*i-1); % entries 1,3,5,...,31 in ppmList (#31 being 0) 
end 
  
for i=1:Nspecs/2-1;     % i=1:15 
                            
    Ztemp(Nspecs-i)=ZSpec(2*i); % So temp(31:-1:17) equals the negative 
    temp(Nspecs-i)=ppmList(2*i); % entries 2,4,6,...,30 in ppmList. 
end 
  
Ztemp(Nspecs)=ZSpec(Nspecs); 
temp(Nspecs)=ppmList(Nspecs); % So temp(32)=ppmList(32), the reference spec 
  
ZSpec=Ztemp';  % The Z-Spectrum and   
ppmList=temp'; % ppmList are now ordered correctly, e.g. 12,6,...0,...,-6,-
12,Ref 
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ZSpec=100*ZSpec/ZSpec(length(ZSpec)); % Normalize the Z-Spectrum to the 
                                      % reference spectrum                                   
  
% Make the MTRasym based on the Z-Spectrum. 
ppms=ppmList(1:length(ppmList)/2); % Picks out the first half (16) of the 
values 
MTRasym=zeros(length(ZSpec)/2,1);  % (16) 
ZSpec=ZSpec(1:length(ZSpec)-1);    % Removes the value from reference 
spectrum (31) 
for i=1:(length(ZSpec)-1)/2;       % i=1:15 
                                                      % The MTRasym 
calculation 
                                                      % i=1:ZSpec(31)-
ZSpec(1) 
    MTRasym(i)=ZSpec(length(ZSpec)-i+1)-ZSpec(i);     % i=2:ZSpec(30)-
ZSpec(2) 
                                                      %          | 
                                                      % i=15:ZSpec(17)-
ZSpec(15)     
end                                                   % Note still 0 at end. 
  
AUC=-trapz(ppms,MTRasym); % Total MTRasym AUC.  Note the negative since the  
                          % ppm values decrease 
   
  
% Double check that there is a MTRasym value for the offset of 2.5 ppm since 
% this is likely to be important and was not always acquired in some initial  
% studies.  If not, then calculate a new value using linear interpolation. 
if isempty(find(ppmList==2.5))==1 
    a=find(ppms>2.5); 
    a=a(length(a)); 
    ppms(a); 
    NewValue=MTRasym(a)+(ppms(a)-2.5)*((MTRasym(a+1)-MTRasym(a))/(ppms(a)-
ppms(a+1))); 
    ppmsNew=[ppms(1:a)' 2.5 ppms(a+1:length(ppms))']'; 
    MTRasymNew=[MTRasym(1:a)' NewValue MTRasym(a+1:length(MTRasym))']'; 
else 
    ppmsNew=ppms; 
    MTRasymNew=MTRasym; 
end 
  
% Plot the Z-Spectrum and MTRasym. 
ppmList=ppmList(1:length(ppmList)-1); % (31) 
figure(1)   
plot(ppmList,ZSpec,'k') 
hold on 
plot(ppmsNew,MTRasymNew,'k') 
set(gca,'XDir','Reverse') 
  
% Now calculate a more 'local' MTRasym value, either the value at the 
% expected offest, or in the region around the expected offest. 
  
                            % ppmTarget is either the value of the expected 
if prod(size(ppmTarget))>1; % max CEST effect or a range [min max] around 
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                            % that expected value. 
                             
    adiff=find(ppmsNew-ppmTarget(1)==min(abs(ppmsNew-ppmTarget(1))));         
    bdiff=find(ppmsNew-ppmTarget(2)==min(abs(ppmsNew-ppmTarget(2))));    
    CESTdiff=-trapz(ppmsNew(adiff:bdiff),MTRasymNew(adiff:bdiff)); 
else 
    adiff=find(ppmsNew-ppmTarget==min(abs(ppmsNew-ppmTarget))); 
    CESTdiff=MTRasymNew(adiff); 
end 
  
% Calculate the 0 ppm shift by fitting to a Lorentzian, which is  
% described by its height, width, offset from 0, and asymptotic value 
  
% Defines the region over which to fit. 
FitRegion=[find(ppmList<=0.3 & ppmList>=-3)']; 
  
% Calculate the initial parameters to use for the fit 
dc0=100; 
Zero=find(ppmList==0); 
Height0=dc0-ZSpec(Zero); 
a=find(ZSpec<Height0/2); 
a=a(1); 
Width0=2*abs(ppmList(a)); 
     
% Define the data needed for the lsqcurvefit function 
xdata=ppmList(FitRegion); 
ydata=ZSpec(FitRegion); 
     
                        % Calls the script to generate the string  
l=CESTShiftLorentzian;  % describing the upside-down Lorentzian which  
                        % is used for the fit. 
                     
fiteqn=inline(l,'x','xdata'); 
p0=[Height0 Width0 dc0 0]; % The initial parameters. 
opts=optimset('MaxIter',100,'MaxFunEvals',2000); % Parameters used by 
                                                 % the fitting routine  
     
% Performs the curve fit 
[param,ressum,residual,exitflag,output]=lsqcurvefit(fiteqn,p0,xdata,ydata,[],
[],opts); 
  
% Extract the values of the parameters from the curve fit 
Height=param(1); 
Width=param(2); 
dc=param(3); 
xo=param(4); % This is the 0 ppm shift. 
  
% Plot the fit Z-Spectrum along with the data points used to fit 
FitZSpec=dc-(Height./(4*((ppmList-xo)/Width).^2+1)); 
plot(ppmList(FitRegion),FitZSpec(FitRegion),'r') 
plot(xdata,ydata,'r*') 
    
if nargin==4;   % In case the center  
    xo=Center;  % of the Z-Spectrum is   
end             % known or should be specefied. 
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% Now correct the Z-spectrum.  This is done by first shifting the original  
% ppm voffset values and then using these values to interpolate the 
% Z-Spectrum to find the new corrected values. 
  
ppmListCorr=ppmList-xo; 
%plot(ppmListCorr,ZSpec,'g*') 
%hold on 
  
ZSpecCorr=zeros(length(ZSpec),1); 
for i=1:length(ppmList); 
    a=find(ppmListCorr>ppmList(i)); 
    b=find(ppmListCorr<ppmList(i)); 
  
    if (isempty(b)==0 & isempty(a)==0); 
        a=a(length(a)); 
        b=b(1); 
        deltax=ppmList(i)-ppmListCorr(b); 
        ZSpecCorr(i)=ZSpec(b)+((ZSpec(a)-ZSpec(b))*deltax/(ppmListCorr(a)-
ppmListCorr(b))); 
    else 
        ZSpecCorr(i)=ZSpec(i); 
    end 
end 
  
% Recalculate the MTRasym. 
MTRasymCorr=zeros(length(MTRasym),1); 
for i=1:(length(ZSpecCorr)-1)/2; % i=1:15 
                                                                    % The 
MTRasym calculation 
                                                                    % 
i=1:ZSpec(31)-ZSpec(1) 
    MTRasymCorr(i)=ZSpecCorr(length(ZSpecCorr)-i+1)-ZSpecCorr(i);   % 
i=2:ZSpec(30)-ZSpec(2) 
                                                                    %          
| 
                                                                    % 
i=15:ZSpec(17)-ZSpec(15)     
end                                                                 % Note 
still 0 at end. 
  
AUCCorr=-trapz(ppms,MTRasymCorr); % Total MTRasym AUC.  Note the negative  
                                  % since the ppm values decrease 
  
% As before, insert a value at 2.5 ppm of necessary. 
if isempty(find(ppmList==2.5))==1 
    a=find(ppms>2.5); 
    a=a(length(a)); 
    ppms(a); 
    NewValue=MTRasymCorr(a)+(ppms(a)-2.5)*((MTRasymCorr(a+1)-
MTRasymCorr(a))/(ppms(a)-ppms(a+1))); 
    ppmsNew=[ppms(1:a)' 2.5 ppms(a+1:length(ppms))']'; 
    MTRasymCorrNew=[MTRasymCorr(1:a)' NewValue 
MTRasymCorr(a+1:length(MTRasymCorr))']'; 
else 
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    MTRasymCorrNew=MTRasymCorr; 
end 
                                                                
% Now recalculate the more 'local' MTRasym value, as done previously.  
  
                            % ppmTarget is either the value of the expected 
if prod(size(ppmTarget))>1; % max CEST effect or a range [min max] around 
                            % that expected value. 
                             
    CESTdiffCorr=-trapz(ppmsNew(adiff:bdiff),MTRasymCorrNew(adiff:bdiff)); 
else 
    CESTdiffCorr=MTRasymCorrNew(adiff); 
end 
                           
plot(ppmList,ZSpecCorr,'b') 
plot(ppmsNew,MTRasymCorrNew,'b') 
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 function 
[AUC,Bo,MTRasymAvg,x,y]=MakeMTRImage(ppmList,ZImage,ppmTarget,PlotFlag,x,y) 
  
% [AUC,Bo,MTRasymAvg,x,y]=MakeMTRImage(ppmList,ZImage,ppmTarget,PlotFlag,x,y) 
% 
% MakeMTRImage.m calculates the MTRasym function on a pixel by pixel 
% basis from a Z-image.  It applies a lorentzian fit to the region near 0 
% and uses the fit to correct the ppm values for any offset from 0 ppm.   
% The Z-Spectrum is then corrected by linear interpolation and the  
% MTRasym is calculated as MTR = (S(-w)-S(w))/So.  The AUC under the MTRasym 
% curve is calculated over the spectral region defined by 'ppmTarget' and the  
% final output is a matrix of the AUC values for each pixel. 
% 
% Input parameters are as follows: 
% 
% ppmList - vector of ppm offset values used to make the Z-Spectrum  
% ZImage - A 3D matrix of all the images corresponding to each value in 
ppmList 
% ppmTarget - region of the MTRasym curve to integrate over for the final 
%   CEST measurement ([2.5 .5]) 
% PlotFlag = 1 if you want to plot the average Z-Spectrum and MTRasym for 
%   the ROI specified by x and y 
% x and y - vectors containing the x and y coordinates of the ROI specified 
%   using the roipoly command (if already defined for the first image in a 
%   time series, then can be reused for subsequent images) 
% 
% Output parameters as follows: 
% 
% AUC - matrix of MTRasym AUC values at each pixel 
% Bo - matrix of Bo offsets 
% MTRasymAvg - average MTRasym for the whole ROI (onle meaningful for a 
%   small, uniform ROI. 
% x and y - same as above, they are also outputs if they are to be reused 
% 
  
  
% Re-order the ppmList and ZSpec values as it is expected here that the  
% ppm offsets are symmetric about 0 and that the spectra have been  
% acquired in an alternating fashion (e.g. +9,-9,+8.5,-8.5,0.1,-
0.1,...,0,RefFreq). 
% Examples noted in the comments below will be for 32 ppm offsets. 
  
a=size(ZImage); 
m=a(1); 
n=a(2); 
Nspecs=a(3);  % Total # of spectra = 32 
Ztemp=zeros(size(ZImage)); 
for i=1:Nspecs/2;                    % i=1:16 
    Ztemp(:,:,i)=ZImage(:,:,2*i-1);  % So Ztemp(:,:,1:16) equals the positive 
offsets 
    temp(i)=ppmList(2*i-1);          % entries 1,3,5,...,31 in ppmList (#31 
being 0) 
end 
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for i=1:Nspecs/2-1;                      % i=1:15 
    Ztemp(:,:,Nspecs-i)=ZImage(:,:,2*i); % So Ztemp(:,:,31:-1:17) equals the 
negative 
    temp(Nspecs-i)=ppmList(2*i);         % entries 2,4,6,...,30 in ppmList. 
end 
  
Ztemp(:,:,Nspecs)=ZImage(:,:,Nspecs); 
temp(Nspecs)=ppmList(Nspecs); % So temp(32)=ppmList(32), the reference spec 
  
ZImage=Ztemp;   % ZImage and  
ppmList=temp';  % ppmList are now ordered correctly, e.g. 12,6,...0,...,-6,-
12,Ref 
  
figure(1); 
imagesc(ZImage(:,:,Nspecs));    % Display CEST image at the reference offset 
colormap(gray);                 % for use in defining the ROI  
colorbar; 
  
if nargin==4; 
    BW=roipoly;         % If an ROI has not yet been defined, then use  
    [x,y]=find(BW);     % the roipoly function to define one 
end 
     
ppms=ppmList(1:Nspecs/2);   % Allocate space for some space 
MTRasym=zeros(Nspecs/2,1);  % for important vectors before 
ppmList=ppmList(1:Nspecs-1);% the main loop 
  
Bo=zeros(m,n);      % Allocate space for some important          
AUC=zeros(m,n);     % Matrices befor ethe main loop 
  
ZSpecAvg=zeros(Nspecs-1,1);     % Allocate space for the average 
MTRasymAvg=zeros(Nspecs/2,1);   % quantities 
  
% Here's the main loop to step through all the pixels in the image 
% defined by the ROI specified in x and y 
for j=1:length(x); 
    ZSpec=zeros(Nspecs,1); 
    for k=1:Nspecs; 
        ZSpec(k)=ZImage(x(j),y(j),k);       
    end 
    ZSpec=100*ZSpec/ZSpec(Nspecs);      % Normalize the Z-Spectrum to the 
                                        % reference spectrum                                   
  
    ZSpec=ZSpec(1:Nspecs-1); % Removes the value from reference spectrum 
  
    % Calculate the 0 ppm shift by fitting to a Lorentzian, which is  
    % described by its height, width, offset from 0, and asymptotic value 
  
    % Defines the region over which to use the data to fit 
    FitRegion=[find(ppmList<=0.3 & ppmList>=-3)']; 
         
    % Calculate the initial parameters to use for the fit 
    dc0=100; 
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    Zero=find(ppmList==0); 
    Height0=dc0-ZSpec(Zero); 
    lw=find(ZSpec<Height0/2); 
    if isempty(lw)==0; 
        lw=lw(1); 
        Width0=2*abs(ppmList(lw)); 
        if Width0==0;                               % These safeguard 
            Width0=(max(ppmList)-min(ppmList))/4;   % against unrealistic 
        end                                         % values for the  
    else                                            % line width 
        Width0=(max(ppmList)-min(ppmList))/4; 
    end 
             
    % Define the data needed for the lsqcurvefit function 
    xdata=ppmList(FitRegion); 
    ydata=ZSpec(FitRegion); 
     
                            % Calls the script to generate the string  
    l=CESTShiftLorentzian;  % describing the upside-down Lorentzian which  
                            % is used for the fit. 
                     
    fiteqn=inline(l,'x','xdata'); 
    p0=[Height0 Width0 dc0 0]; % The initial parameters. 
    opts=optimset('MaxIter',100,'MaxFunEvals',2000,'Display','none'); % 
Parameters used by 
                                                                      % the 
fitting routine  
         
    % Performs the curve fit 
    
[param,ressum,residual,exitflag,output]=lsqcurvefit(fiteqn,p0,xdata,ydata,[],
[],opts); 
  
    % Extract the values of the parameters from the curve fit 
    Height=param(1); 
    Width=param(2); 
    dc=param(3); 
    xo=param(4); % This is the 0 ppm shift. 
  
    if abs(xo)>1; 
        xo=0; 
    end 
   
    Bo(x(j),y(j))=xo; 
  
    % Now correct the Z-spectrum.  This is done by first shifting the 
original  
    % ppm voffset values and then using these values to interpolate the 
    % Z-Spectrum to find the new corrected values. 
  
    ppmListCorr=ppmList-xo; 
  
    ZSpecCorr=zeros(length(ZSpec),1); 
    for k=1:length(ppmList); 
        a=find(ppmListCorr>ppmList(k)); 
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        b=find(ppmListCorr<ppmList(k)); 
             
        if (isempty(b)==0 & isempty(a)==0); 
            a=a(length(a)); 
            b=b(1); 
            deltax=ppmList(k)-ppmListCorr(b); 
            ZSpecCorr(k)=ZSpec(b)+((ZSpec(a)-
ZSpec(b))*deltax/(ppmListCorr(a)-ppmListCorr(b))); 
        else 
            ZSpecCorr(k)=ZSpec(k); 
        end 
    end 
     
    % Calculate the MTrasym 
    for k=1:Nspecs/2-1 % k=1:15 
                                                                      % The 
MTRasym calculation 
                                                                      % 
k=1:ZSpec(31)-ZSpec(1) 
            MTRasym(k)=ZSpecCorr(length(ZSpecCorr)-k+1)-ZSpecCorr(k); % 
k=2:ZSpec(30)-ZSpec(2) 
                                                                      %          
| 
                                                                      % 
k=15:ZSpec(17)-ZSpec(15)     
    end                                                               % Note 
still 0 at end. 
  
    % Insert a value at 2.5 ppm if necessary.  This is based on the 
    % observation that [2.5 0.5] is likele to be the best region to 
    % integrate the MTRasym over, but initial studies did not incluse 
    % 2.5 ppm as an offset.  Future studies will all include 2.5 ppm so 
    % this will become unnecessary. 
    if isempty(find(ppmList==2.5))==1 
        a=find(ppms>2.5); 
        a=a(length(a)); 
        ppms(a); 
        NewValue=MTRasym(a)+(ppms(a)-2.5)*((MTRasym(a+1)-
MTRasym(a))/(ppms(a)-ppms(a+1))); 
        ppmsNew=[ppms(1:a)' 2.5 ppms(a+1:length(ppms))']'; 
        MTRasymNew=[MTRasym(1:a)' NewValue MTRasym(a+1:length(MTRasym))']'; 
    else 
        ppmsNew=ppms; 
        MTRasymNew=MTRasym; 
    end                    
                                   
    % Now calculate the more 'local' MTRasym value  
  
                                % ppmTarget is either the value of the 
expected 
    if prod(size(ppmTarget))>1; % max CEST effect or a range [min max] around 
                                % that expected value. 
                             
        adiff=find(ppmsNew-ppmTarget(1)==min(abs(ppmsNew-ppmTarget(1))));         
        bdiff=find(ppmsNew-ppmTarget(2)==min(abs(ppmsNew-ppmTarget(2))));                        
        CESTdiffCorr=-trapz(ppmsNew(adiff:bdiff),MTRasymNew(adiff:bdiff)); 
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    else 
        adiff=find(ppmsNew-ppmTarget==min(abs(ppmsNew-ppmTarget))); 
        CESTdiffCorr=MTRasymNew(adiff); 
    end 
         
    AUC(x(j),y(j))=CESTdiffCorr; 
      
    ZSpecAvg=ZSpecAvg+ZSpecCorr;    % Keeps a running total of the ZSpec 
    MTRasymAvg=MTRasymAvg+MTRasym;  % and MTRasym to calculate the average 
     
end 
  
ZSpecAvg=ZSpecAvg/length(x);        % Calculates the average ZSpec and 
MTRasymAvg=MTRasymAvg/length(x);    % MTRasym for the ROI 
  
% Plot the MTRasym AUC map 
figure(2); 
imagesc(AUC,[-5 15]); 
colormap(gray); 
colorbar; 
  
% Plot the Bo map 
figure(3); 
imagesc(Bo,[-0.5 0.5]); 
colormap(gray); 
colorbar; 
        
% If a plot of the average Z-Spectrum and MTRasym is desired, this could  
% useful if a small ROI is used 
if PlotFlag==1; 
    figure(4); 
    plot(ppmList,ZSpecAvg,'k'); 
    hold on; 
    plot(ppmList(1:length(MTRasymAvg)),MTRasymAvg,'k'); 
    set(gca,'XDir','Reverse') 
end 
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